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ABSTRACT

The study of factors promoting b-sheet formation has recently gained interest due to
the suspected involvement of b-sheets in brain degenerative diseases such as Alzheimer’s
disease (AD), Creutzfeldt-Jacob disease (CJD) and bovine spongiform encephalopathy.
Understanding b-sheet formation and the factors that stabilize b-sheet structure may serve
as a basis for future drug design. The extended structure of a b-sheet can be stabilized by
constrained amino acid analogs that are pre-organized to adopt the extended conformation.
In this dissertation using innovative synthetic organic chemistry methods, two dipeptide
units are designed and synthesized that are constrained to form the extended conformation
and mimic the hydrogen-bonding and side chain interactions that natural b-sheets form
along one edge of the individual peptide strands. DiPeptideUnit (DPU) 45 and AzaDiPeptide unit (ADP) 46 are designed to have increasing levels of constraint in order to
directly measure the relative b-sheet forming propensity of the constrained dipeptides when
incorporated into selected positions of a prototypical, “semi-stable” b-hairpin peptide.
An improved synthesis of DPU(Gly, Xxx) 45 from

D-glutamic

acid is reported.

Previously described syntheses of lactam-constrained dipeptide amino acids involve
lengthy and expensive procedures to obtain an aldehyde intermediate. The key to the
synthesis of the DPU(Gly, Xxx) 45 is the convenient synthesis of an a-amino acid
semialdehyde in high yields. When DPU(Gly, Leu) 47b is incorporated into an analogous
peptide it stabilizes the b-sheet secondary structure according to CD measurements and this
stabilizing effect is higher when more DPU residues are incorporated.

ix

A very efficient way of synthesizing ADP(Gly, Phe) 46 is also reported. The key
intermediate in this synthesis is a protected a-hydrazino ester derivative that is synthesized
from a-amino esters using inexpensive reagents and in excellent overall yields. The key
reaction step in the synthesis is the very effective coupling of a D-aspartic acid derivative
with the Na of the a-hydrazino ester by symmetrical anhydride method.

x

CHAPTER 1
INTRODUCTION
1. 1

Proteins and Peptides
Proteins and peptides are linear polymers consisting of 20 natural amino acids that

are linked together by amide bonds. Short chains of amino acids, two to about forty
residues, are known as peptides. Longer chains containing more than thirty residues are
called as polypeptides. Proteins are polypeptides with defined structure.
In nature, there is an enormous number of different proteins that fold into various
structures and carry out many diverse functions. The biological function of a protein
depends on its folded three-dimensional structure.

Proteins fold into well-defined

secondary and tertiary structures, either spontaneously, as determined by their amino acid
sequences, or with the assistance of chaperones (Williamson, 1992; Ellis, 1989). Folded
proteins display considerable conformational diversity at the tertiary structure level,
whereas they can be described in terms of simpler secondary structure elements; a-helices,
b-sheets, loops and turns. These structures are stabilized by many noncovalent interactions
such as hydrogen bonds, hydrophobic effects, electrostatic and steric interactions.
Proteins fold by the counterbalancing of favorable and unfavorable enthalpic and
entropic contributions that make most native protein structures just 5-15 kcal/mol more
stable than denatured forms of the protein (Branden & Tooze, 1999). The modest stability
of native proteins makes the exquisite level of biological regulation and structural
dynamics that proteins exhibit possible. Enthalpy contributions to native protein folding
stability are often quite favorable compared to the denatured protein, whereas entropy
contributions are significantly positive in the native protein fold or unfavorable compared
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to the denatured protein structure at 37 ºC. A solution of 1015 proteins in a denaturing
solution, where every protein potentially has a different structure, has significantly more
disorder than the completely folded protein solution in spite of a greater number of specific
solvent interactions required to solvate the unfolded protein. While many proteins fold to
their global minima without being trapped in local minimas, sometimes proteins require the
assistance of chaperones to fold into their native forms. The protein chaperones are
generally believed to function by preventing premature protein aggregation (Branden &
Tooze, 1999; Lesk, 2001).
Protein folding is a complex process and many diseases depend on misfolding of
proteins.

The consequences of reduced protein folding stability have been studied

extensively by site-directed mutagenesis of proteins.

One of the most well known

examples of natural single-site mutation causing significant problems is the sickle cell
defect of hemoglobin. A single mutation of an amino acid in hemoglobin causes increased
aggregation of deoxyhemoglobin leading to a clinically significant disease (Lesk, 2001).
Often single or multiple mutations of natural proteins alter the overall protein structures,
making these overall protein structures nearly interchangeable with the starting protein
structure.

There are many sites in proteins where a single amino acid change will

destabilize the folded protein structure and make the denatured form of the protein more
stable than the folded protein structure. When this occurs in nature, the denatured protein
is usually quickly destroyed by intracellular proteases and this could be lethal if the protein
was essential for cell life. In the last few years, many diseases have been shown to arise
from protein misfolding without any alteration of the proteins’ primary structure. The most
well known examples are the neurodegenerative diseases such as Alzheimer’s disease,
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Parkinsons’s disease, Creutzfeld-Jacob disease, and many other prion diseases (Prusiner,
1995; Taubes, 1996; Mestel, 1996). In each of these diseases, abnormal folding of a
normal soluble protein results in the formation of insoluble aggregates called amyloid
plaques. Although amyloid plaques formed in each of these diseases consist of completely
different polypeptides with regard to their primary structure, their morphological and
ultrastructural features are similar to each other (Rochet, 2000; Lansbury, 1992; Koo,
1999). The amyloid deposits are composed of protein fibrils rich in b-sheet structures.
Although it is not clear at present whether the misfolding triggers protein aggregation or
rather protein oligomerization induces the conformational changes, b-sheet formation
appears to be critical in the aggregation process.
1. 2

b-Sheets in Amyloid-associated Diseases
In Alzheimers’s disease, the primary protein component of these plaques is

amyloid-b (Ab) peptide, a 40-42 amino acid fragment cleaved from the membrane-bound
amyloid precursor protein (APP). Ab is an amphiphilic peptide that spontaneously selfassembles into amyloid fibrils with cross-b-sheet conformation (Kirschner, 1986). b-sheets
that form in the b-amyloid deposits are believed to have parallel registry (Benzinger, 1998;
Esler, 1996; Burkoth, 1998; Gregory; 1997). b-amyloid deposition is neurotoxic and may
be important in the progression of the disease.
The design and synthesis of compounds that would disrupt or block the aggregation
of Ab into b-amyloid fibrils and inhibit its neurotoxicity is an active area of research.
Many small molecules such as Congo red 1, hexadecyl-N-methylpiperidinium bromide 2,
and b-cyclodextrin 3, which have affinity for the cross-b-sheet structural domains typical
of amyloid fibrils, are reported to distrupt Ab aggregation and reduce Ab toxicity by
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binding to a site on Ab which is necessary for Ab self assembly (Figure 1) (Lorenzo, 1994;
Wood, 1996; Camilleri, 1994). Conjugated cyclic compounds such as anthracyclines 4,
benzofurans 5, pyridones 6 and rifampicin 7 are also reported to have antitoxic and/or
antiaggregation activities (Figure 1) (Howlett, 1999a & 1999b; Kuner, 2000; Tomiyama,
1996).

Figure 1. Structures of compounds with reported antitoxicity and/or antiaggregation
activity; Congo red 1, hexadecyl-N-methylpiperidinium bromide 2, b-cyclodextrin 3,
representative compounds for anthracyclines 4, benzofurans 5, pyridones 6, rifampicin 7.
4

Several peptides containing sequences from Ab were generated with the idea that a
fragment of Ab should selectively bind Ab, occupy a target site for aggregation and
directly interfere with fibril formation. The amino acid sequence of Ab-(1-42) is Asp1Ala2-Glu3-Phe4-Arg5-His6-Asp7-Ser8-Gly9-Tyr10-Glu11-Val12-His13-His14-Gln15-Lys16Leu17-Val18-Phe19-Phe20-Ala21-Glu22-Asp23-Val24-Gly25-Ser26-Asn27-Lys28-Gly29-Ala30Ile31-Ile32-Gly33-Leu34-Met35-Val36-Gly37-Gly38-Val39-Val40-Ile41-Ala42.

Ab has three

notable regions: a hydrophilic N-terminus Ab (1-16), a central hydrophobic region Ab (1721) and a long hydrophobic C-terminus Ab (29-42).
Tjernberg et al. reported that Lys-Leu-Val-Phe-Phe, matching the sequence of Ab
(16-20), binds to and disrupts fibril formation (Tjernberg, 1996 & 1997). Hughes et al.
reported that an octapeptide Gln-Lys-Leu-Val-Thr-Thr-Ala-Glu, matching the sequence of
Ab (15-22), where each of the Phe residues at positions 19 and 20 are substituted with Thr
residues inhibits the fibril formation at a 10-fold molar excess compared with the native
protein (Hughes, 1996). Kiessling, Murphy and coworkers reported that attachment of the
sequence of Ab (15-25) (recognition element), to a poly(Lys) unit (amyloid disrupting
element) retards Ab-aggregation and blocks Ab toxicity in vitro (Ghanta, 1996). The
choice of the recognition element is based on the fact that the interior sequence Ab (17-20)
is crucial to the formation of cross b-fibrils and this region has been implicated in Ab selfrecognition (Hilbich, 1992). Attachment of polar hydrophilic functionality, poly(Lys) unit,
to the recognition element is to offer a molecule that could bind to Ab but would not form
fibrils. The two peptides tested are NH2-Lys-Lys-Lys-Lys-Lys-Lys-Gly-Gly-Gln-Lys-LeuVal-Phe-Phe-Ala-Glu-Asp-Val-Gly-COOH and NH2-Gly- Gln-Lys-Leu-Val-Phe-Phe-AlaGlu-Asp-Val-Gly-Glya-Lys-Lys-Lys-Lys-Lys-Lys-COOH and the latter is reported to have
5

more dramatic effects on the aggregation properties of b (1-39), which indicates that the
location of the poly(Lys) unit is a critical feature in the properties of these peptides and the
hydrophobicity of the C-terminal sequence plays an important role in the formation and
stability of Ab-amyloid fibrils.
The formation of b-sheets and fibrils is also involved in familial amyloid
polyneuropathy and senile systemic amyloidosis disease. These diseases are associated
with transthyretin (TTR) amyloid fibrils, which are believed to form in the acidic partial
denaturing environment of the lysosome (Colon, 1992; Lai, 1996). TTR is composed of
four identical 127-amino acid b-sheet-rich subunits. The mechanism of TTR amyloid fibril
formation requires the dissociation of the tetrameric structure into a monomeric
conformational intermediate, which then aggregates to form amyloid fibrils. Rather than
directly blocking the aggregate formation as mentioned above, Kelly and coworkers
reported that amyloid fibril formation could be prevented by stabilizing the normal fold of
TTR against the pH-mediated dissociation and conformational changes associated with
fibril formation. The interaction of TTR with the small-molecule inhibitor, flufenamic acid
(Flu) 8, (Figure 2) mediates intersubunit hydrophobic interactions and hydrogen bonds that
stabilizes the normal tetrameric fold of TTR (Peterson, 1998).

Figure 2. Structure of flufenamic acid.
6

1. 3

b-Sheets in HIV Infection and AIDS
In addition to amyloid diseases, involvement of b-sheets is also observed in HIV

infection and AIDS. Proteases are enzymes, which cleave proteins at specific peptide
bonds. Many proteases bind their substrates and inhibitors by generating b-sheets/strands
(Smith, 1994). HIV protease, an enzyme responsible for the maturation of HIV into
infectious particles, is a C2 symmetric homodimer (Figure 3) in which each monomer

Figure 3. Molecular representation of HIV-1 protease dimerization interface.
7

consists of 99 amino acids with similar conformations. The dimerization interface is
composed by interdigitating the N- and C-terminal portions of the protease into a fourstranded-antiparallel-b-sheet. This interaction has been shown to be essential for HIV
protease activity.
The development of protease inhibitors has been facilitated by the determination of
a three dimensional structure of the HIV-1 protease. In the protease, the N-terminal ends
of residues Pro (1) and Cys (95) are held at a distance of approximately 10 Å. A flexible
flap allows for hinge-like mobility, which allows substrate/inhibitor access to the active site
by opening and folding the tips into hydrophobic pockets thus exerting an important role in
protease activity. HIV-1 is an aspartic acid protease and the active-site triad Asp25-Thr26Gly27, is located in a loop, which is stabilized by a network of hydrogen bonds.
1. 3. 1

FDA Approved HIV Protease Inhibitors

All of the HIV protease inhibitors that have been approved and most of which in
development are designed to interact with the active site preventing the binding of enzyme
natural substrates. These inhibitors are small linear peptides or peptidomimetic compounds
containing non-hydrolysable transition-state analogs.

The cleavage site at the peptide

linkage is replaced by transition-state isosteres, such as hydroxyethylamine which is found
in all of the currently approved drugs; saquivanir 9, nelfinavir 10, ritonavir 11, indinavir
12, amprenavir 13, and lopinavir 14 (Figure 4) (Craig, 1991; Patick, 1996; Sham, 1998;
Dorsey, 1994; Vacca, 1994; Kim, 1995; Sham, 2002). These flexible inhibitors strongly
bind to the HIV-1 protease due to a favorable combination of specific electrostatic and
hydrophobic interactions between the enzyme and the inhibitors. However, a protease
inhibitor must adopt an extended conformation to have its most favorable binding with the
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protease, which results in loss of conformational entropy. Whereas, inhibitors having the
same specific electrostatic and hydrophobic interactions and that are pre-organized to adopt
the favorable extended conformation, do not lose as much conformational entropy when
they bind with the protease in an extended conformation. In other words conformationally
constrained inhibitors can bind with much greater affinity and be much more potent
inhibitors (Bartlett, 2001; Meyer, 1998).

Figure 4. Most recent hydroxyethylamine-based HIV protease inhibitors approved by
FDA; saquivanir 9, nelfinavir 10, ritonavir 11, indinavir 12, amprenavir 13, and lopinavir
14.
9

In crystal structures of linear peptidic inhibitors it was found that a conserved water
molecule is mediating the contacts between the amide hydrogens of Ile50 and Ile150 in the
enzyme and the carbonyl oxygens of the inhibitors by bridging a hydrogen bonding
network between them. This tetrahedrally coordinated water, called water number 301
(Wat301), is believed to play a key role in helping to stabilize the extended conformation
of linear inhibitors.
1. 3. 2

Nonpeptidic HIV Protease Inhibitors

Only a few nonpeptidic HIV-1 protease inhibitors have been reported to be preorganized to adopt the extended conformation before binding. The best examples are
dihydroxyethyl-based cyclic urea inhibitors pioneered at DuPont Merck, DMP-323 15, SD146 16,and SD-152 17 (Figure 5) (Lam, 1994; Ala, 1998; Jadhav, 1997). Inhibitors 15 and
16 have been designed to be symmetrical to take advantage of the C2 symmetry of the

Figure 5. Chemical structures of symmetrical 15, and 16 and non-symmetrical 17 cyclic
urea based HIV-1 protease inhibitors in which an oxygen atom replaces Wat301.
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homodimeric enzyme and have two appropriately spaced oxygen atoms, one capable of
replacing water number 301, and the other able to bind to one or both of the active site
aspartates. Although symmetrical inhibitors can result in tight binding and offer simple
synthetic pathways, symmetrical compounds appear to be more susceptible to viral
resistance. This is a major disadvantage because a single mutation in the protease can have
multiplicative effects on inhibitor binding and the AIDS retrovirus has a seemingly
limitless capacity to evolve drug resistance mutations.
Sham and coworkers have reported a series of nonpeptide azacyclic ureas and
compound 18, with a Ki of 5 pM, is one of the most potent HIV-1 protease inhibitor
reported ever (Sham, 1996). It is about 1000 times more active than any of the approved
drugs mentioned previously (Figure 6).

It is constrained to adopt an extended-like

conformation at the active site of the enzyme. The urea carbonyl of 18 replaces the
position normally occupied by Wat301 observed in crystal structures of linear peptidic
inhibitors. X-ray crystallographic analysis of compound 18 indicates strong hydrogen
bonding interactions between the inhibitor’s methoxy/hydroxy oxygens and the main chain
N-H of Asp 29, Asp30, Asp 129 and Asp 130. It is believed that all these favorable
interactions and the extended structure of compound 18 account to some extent for the
higher affinity of this inhibitor.

Figure 6. One of the most potent HIV-1 protease inhibitors designed by Sham et al.
11

1. 3. 3 Interfacial Inhibitors of HIV-1 Protease
Many research groups have used peptides from the b-sheet dimerization interface of
HIV-1 protease to interrupt dimerization of the protease and inhibit protease activity. Craik
and coworkers showed that HIV-1 protease activity was reduced in the presence of HIV-2
protease (Babe, 1991). They further concluded that the heterodimer of HIV-1 and HIV-2
formed a similar four-stranded b-sheet that had significantly reduced activity compared to
the homodimer. This encouraged the developments of analogous peptide-based approach
structures to effectively inhibit HIV-1 protease activity.
Chmielewski and coworkers tested cross-linked peptides with polymethylene and
amine based tethers from the N- & C- termini of the protease as interfacial inhibitors of
HIV-1 protease (Figure 7) (Shultz, 1997). They reported that peptides with methylene
tethers 19 both inhibit HIV-1 protease activity and decrease the amount of protease dimer
solution, whereas, peptides with hydrophilic 20 and bulky 21 tethers have decreased
inhibitor effectiveness by approximately 10- and 2- fold, respectively, compared to simple
methylene tethers. It is concluded that hydrophobic interactions is the primary driving
force for inhibitor-protease association, whereas hydrogen bonding and electrostatic
interactions play much smaller role. They further reported that the chain length of 14
atoms for methylene tethers and chain length of 13 atoms for amines and their derivatives
are the most effective inhibitors because these linkers are sufficiently long to span the 10 Å
of the interdigitated strands.
Sicsic and coworkers designed and synthesized conformationally constrained
“molecular tongs” and showed that with a more rigid spacer (naphthalene) and a shorter
peptidic sequence (Thr-Leu-Asn-Phe-OMe or Val-Leu-Val-OMe) a potent inhibitor was

12

obtained (Figure 8) (Bouras, 1999). They further concluded that aromatic-based spacers
introduce a steric constraint, which is likely to provide a positive entropic effect in contrast
to highly flexible spacers reported by Chmielewski et al. They also assembled their linker
with a pyridine ring that at neutral pH the positively charged pyridine ring would be
proximate to the C-terminus carboxylate and results in favorable ionic interactions.
Although it is difficult to provide general principles of inhibitor design at this point,
a conclusion could be made as a result of the studies mentioned above; it is possible to
produce active protease inhibitors by targeting the b-sheet dimerization interface of HIV
protease combined with the development of compounds constrained to form extended
conformations.

Figure 7. Design of peptides tested as interfacial inhibitors of HIV-1 protease by
Chmielewski et al.
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Figure 8. Structures of molecular tongs designed by Sicsic et al. (X1 = X2=peptide).

1. 4

b-Sheet Secondary Structure
The solution of the “protein folding problem” requires a complete understanding of

the individual factors that contribute to protein stability.

It has been shown that the

information for folding of a protein to its native conformation is contained in its amino acid
sequence (Anfinsen, 1973). Although it is not yet possible to predict the tertiary structure
of a protein from its amino acid sequence alone, understanding the origins of a-helix and
b-sheet stability should enhance our knowledge of how the helices and sheets pack together
to form tertiary structure.
Peptides that fold in isolation provide a useful way to study protein secondary
structure and stability. The a-helix has been studied in this way for a number of years.
The b-sheet is almost as common as a-helix in proteins. In contrast to the studies of ahelical peptides, the study of b-sheets has not been as successful due to the fact that these
peptides have a propensity to self-associate into large, generally insoluble, quaternary bsheet structures, which makes detailed thermodynamic and structural characterization very
difficult (Pauling 1951a & 1951b). The contrast between the a-helix and b-sheet stability
in model systems comes from the fundamental difference in the hydrogen bonding patterns
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of the two types of secondary structures (Nesloney, 1996; Doig, 1997). In the a-helix,
backbone hydrogen bonding is intrasegmental that connects C=O of the ith residue to the
N-H of (i+4)th residue. This favorable intra-strand interaction allows the a-helix to satisfy
most of its backbone hydrogen bonding needs without help from a partner. In the b-strand,
there is no intra-strand interaction where the C=O and N-H groups are hydrogen bonded to
N-H and C=O groups on adjacent strands. The individual strands that build up the b-sheet
adopt the extended conformation wherein side chains alternate pointing up and down. In
addition to hydrogen bonding interactions, the side chains of the amino acids will interact
with other strands above or below the original strand making the b-strand form favorable
interactions with adjacent strands in four directions (up, down, left, and right). All these
interactions make b-sheets aggregate and precipitate out of solution. For a b-sheet peptide
or protein design to succeed it is not sufficient to control only the favorable interactions but
also control the "unwanted" interactions.
The polypeptide chains in a b-sheet have either the same (parallel) or alternating
(antiparallel) direction.

In parallel b-sheets, the b-strands run in the same amide-to-

carbonyl direction, and the backbone hydrogen bonds are evenly spaced and angle across to
the adjacent main chain.

In antiparallel b-sheets, the hydrogen bonds are formed

approximately perpendicular to the main chain (Figure 9). Parallel b-sheets form slightly
longer complementary hydrogen bonds that are probably compensated with more regular
side chain-side chain packing. Antiparallel b-sheets have shorter complementary hydrogen
bonds with side chain-side chain interactions that alternate pointing slightly toward each
other and slightly away from each other. Parallel b-sheets are more frequently found in the
hydrophobic interior of proteins where the slightly longer hydrogen bonding interactions
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would be somewhat protected from disruption by competing hydrogen bonding interactions
with water molecules. Whereas, antiparallel b-sheets are often found at the surfaces of
proteins and often have amphipathic character.

For a b-sheet to have a significant

amphipathic character the side chains need to alternate polarity with for instance
hydrophobic side chains pointing down and more polar side chains pointing up along the
extended strand.

Figure 9. Hydrogen-bonding pattern for parallel and antiparallel b-strands. Hydrogen
bonds are shown by hatched blocks. Arrows show the amide (N) to carbonyl (C) direction
of the strand.
b-strands can change the direction of the main chain dramatically by 180º through a
b-turn (Figure 10) (Dyson, 1988; Hutchinson, 1994; Sibanda, 1989). b-turns are usually
defined in terms of four amino acid residues and the connecting loop contains the two
central residues of the b-turn. b-bulges are formed by the inclusion of two amino acid
residues on one strand and one amino acid residue on the opposite strand in between two b-
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type hydrogen bonds. b-bulges almost always are found in highly twisted b-structures. bsheets usually exhibit a right-handed twist which is favored by intrastrand nonbonded
interactions and intrastrand geometric constraints (Chothia, 1973; Chou, 1983). A righthanded twist in b-sheets give rise to diagonal contacts between side chains that are not
directly across from one another.

Figure 10. Schematic representation of a b-turn and a b-bulge in an antiparallel b-sheet.

1. 4. 1

b-Hairpin

One of the approaches to study b-sheet structure is to form an intermolecular bsheet where two separate strands would be aggregating to form the b-sheet. The problem
with this approach is large-scale aggregations can occur because it is not always possible to
limit the b-sheet structure to only two strands.
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This difficulty has been overcome by the identification of several short, linear
peptides (£ 16) that display significant b-hairpin formation in aqueous solution (Blanco,
1993 & 1994; Constantine, 1995; Searle, 1995; Stanger, 1998). Figure 11 shows the
structure of a b-hairpin, which is an intramolecular structure that contains two antiparallel
strands and a short connecting loop. It is important to be able to specify the location and
the size of the loop for b-hairpin models to be useful for the study of the antiparallel bsheet stability. Hairpin turns are advantageous not only because they serve as nucleators of
antiparallel b-sheet structure but also hairpins are often the sites for molecular recognition
of proteins.

Figure 11. b-sheet hairpin.

Two approaches gained the most interest in b-hairpin design. One approach is to
design an unnatural amino acid template, which would serve as a b-turn and nucleate bsheet formation. The other approach is to use natural or artificial amino acids in the b-turn
location. The general design strategy for these model peptides is;
a. the selection of the a-amino acids with high intrinsic b-sheet propensities.
Statistical surveys of proteins of known structure have shown that the b-branched and
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aromatic amino acids such as Tyr, Phe, Ile, Thr, Trp, and Val occur most frequently in bsheets, while Gly, Pro and the charged residues (Arg, Lys, and Glu) are among the poorest
b-sheet formers (Chou, 1974).
b. to provide favorable long-range side chain-side chain interactions which hold the
hairpin together. Statistical surveys of proteins of known structure have also shown that
there is a nonrandom pairwise distribution of amino acids in b-sheet structures and the
most interactive pairs are Phe-Phe, Phe-Tyr, Glu-Arg, and Glu-Lys and the least interactive
pairs are Thr-Val and Thr-Trp (Smith, 1997).
c. the positioning of hydrophobic residues across from each other on adjacent
strands since the interactions between hydrophobic side chains contribute to b-sheet
stability.
d. to use basic residues to generate a net positive charge in order to prevent
aggregation at neutral or mildly acidic pH.
Kelly and coworkers incorporated 2, 3¢-substituted biphenyl-based amino acids into
water soluble peptides to replace the two central residues of a b-turn in a b-hairpin like
structure (Figure 12) (Nesloney, 1996). They reported that with the appropriate choice of
the remaining amino acid sequence would support b-sheet structure, peptides with the
sequence hydrophobic a-amino acid-22-hydrophobic a-amino acid form b-hairpin like
structures in aqueous solution. They further reported that the NMR results indicate the
presence of a hydrophobic cluster involving an aromatic ring of 22 and a side chain of one
of the flanking hydrophobic a-amino acids.

For these peptides, increase in b-sheet

structure with increasing temperature is a likely consequence of the temperature
dependence of the hydrophobic effect.

However, incorporation of residue 23 into an
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identical a-amino acid sequence does not result in folding under the same conditions. This
shows that residue 23 is incapable of forming the hydrogen-bonded hydrophobic cluster,
which is necessary for initiating b-sheet structure and b-hairpin folding for these peptides.

Figure 12.
Structures of biphenyl-based amino acids 3¢-(2-aminoethyl)-2biphenylpropionic acid 22 and 2-amino-3¢-biphenylcarboxylic acid 23, and the possible
conformations of peptides containing 22 and 23 designed by Kelly and co-workers.
Rico, Blanco, Searle, and Gellman groups incorporated natural or artificial amino
acids in the b-turn location of a b-hairpin and studied b-hairpin folding in a series of linear
peptides in aqueous solution. The two strategies that have been reported most often for the
initiation of b-hairpin folding with a two-residue loop at a specific site are the use of LAsn-Gly or D-Pro-Xxx as the loop sequence. Rico and Blanco, and Searle groups used LAsn-Gly (at positions i+1 and i+2) because this segment has the highest statistical
correlation with b-turns (Ramirez-Alvarado, 1996; de Alba, 1997; Maynard, 1997). Searle
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and co-workers designed an unconstrained 16-residue linear peptide that folds
autonomously in water into a b-hairpin (Figure 13) (Maynard, 1997).

Figure 13. 16-residue peptide 26 designed by Searle and coworkers containing L-Asn-Gly
a b-hairpin structure in water.
Gellman and co-workers reported a direct comparison of b-hairpin promotion by LAsn-Gly, and D-Pro-Gly (Figure 14) segments by incorporating these residues in the b-turn
location of a 12-residue peptide (Stanger, 1998). They pursued the D-Pro strategy because
proline in the i+1 position 27 strongly stabilizes b-turn conformation. Their results indicate
that D-Pro-Gly segment is a very strong promoter of b-hairpin formation and superior to
the L-Asn-Gly segment. In addition, switching the proline configuration (D-Pro to L-Pro)
completely disrupts b-hairpin folding.

Figure 14. 12-residue peptide designed by Gellman and co-workers that displays b-hairpin
folding in aqueous solution.
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1. 4. 2

b-Sheet Templates

Other research groups have synthesized mostly planar building blocks and incorporated
them into simple to moderately complex peptidomimetics that mimic the complementary
hydrogen-bonding network of b-sheets.

Kemp et al. used diacylaminoepindolidione

templates for nucleation of b-sheet structure in an attached polypeptide chain (Figure 15)
(Kemp, 1988a & 1988b). The template is linked to a dipeptide Pro-D-Ala, since this pair is
presumed to adopt a b-turn conformation (Karle, 1981). Peptide 28 is reported to be the
first b-sheet mimic with a well-defined b-sheet structure. They reported that 28 folds into
an antiparallel b-pleated sheet structure in DMSO. Coupling to urea inverts the direction
of the peptide chain and permits the formation of an antiparallel b-sheet structure 28,
whereas removal of the urea allows the parallel b-sheet formation 29.

Figure 15. First b-sheet mimic 28 reported by Kemp and co-workers that folds into a welldefined antiparallel b-sheet conformation in DMSO. Structure of the peptide which adopts
a b-sheet conformation when urea is removed 29.
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Nowick and co-workers introduced an unnatural amino acid, which behaves like a
regular amino acid in peptide synthesis and induces b-sheet folding and interactions in
peptides in suitable organic solvents (Figure 16) (Nowick, 2001 & 2002). Compound 30,
consists of an ornithine residue and the b-strand mimicking amino acid Hao attached to its
side chain.

They reported that when incorporated into a peptide 31, the Hao group

hydrogen bonds to the three subsequent residues to form a b-sheet like structure. The side
chain of the ornithine residues allows Hao oxalamide carbonyl group to form a hydrogenbonded ten membered ring with the amino group of the subsequent residue, like a b-turn in
a b-hairpin.

Figure 16. Structures of the unnatural amino acid 30 and peptide 31 designed by Nowick
and co-workers where peptide 31 forms a dimeric b-sheet like structure in chloroform.
The Nowick group also designed and synthesized a triple-stranded artificial b-sheet
32 that adopts a folded b-sheet-like conformation in organic solvents (Figure 17) (Nowick,
2001). They designed it so that the top and the bottom strands mimic the hydrogenbonding functionality of peptide b-strands and embrace the middle strand of the sheet. The
middle strand holds the three strands next to each other. It is important to note that a b-
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sheet-like conformation is adopted out of the all other possible conformations this large and
complex molecule can adopt, which shows the success of the design strategy.

Figure 17. Structure of triple stranded artificial b-sheet designed by Nowick and coworkers that adopts a folded b-sheet-like conformation in organic solvents.
The peptide models reported by Kemp and Nowick lack the side chains of natural
extended strands and as a result do not form b-sheet-like interactions in aqueous media.
Conformational stability in aqueous media is important with regard to biological
applications.
1. 4. 3

Constrained b-Strand Mimetics

Rebek and co-workers reported the design of a constrained tetrapeptide mimetic
that mimics the side chain interactions of natural b-sheets better than Nowick’s design
(Figure 18) (Boumendjel, 1996). Compound 33 features a rigid backbone conformation
and displays properly oriented side chains.

Although the synthetic route is not very

practical, it still permits access to a variety of side-chains other than Lys and Phe.
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Figure 18. Constrained tetrapeptide mimetic 33 designed by Rebek and co-workers having
a rigid backbone and properly oriented side chains.
Another example of a constrained b-strand mimic is reported by Bartlett group
(Phillips, 2002).

They reported that their “@-tides” 34 (@-tides refers to alternating

oligomers with amino acids) assume a b-strand-like structure using a 1,2-dihydro-3(6H)pyridinone (also referred to as “Ach” or @), which is a conformationally restricted glycine
mimic (Figure 19). NMR studies showed that incorporation of the Ach unit in a peptide
with natural amino acids at alternate positions, affords an oligomer that exhibits hydrogenbonding characteristics of a peptide in the extended b-strand conformation in chloroform
and chloroform/methanol. The resulting peptidomimetic maintains a regular pattern of
hydrogen-bond donors and acceptors along one face of the strand.

Figure 19. Structure of constrained b-strand mimic reported by Bartlett group with a
regular pattern of hydrogen-bond donors and acceptors along one face of the strand.
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1. 4. 4 Covalent Modification of b-Strands with Methyl Groups
Many research groups proposed that the covalent modification of the main chain in
a b-sheet would prevent formation of a hydrogen-bonded b-sheet and be a general solution
to the problem of b-sheet self-association and aggregation. A two-stranded b-sheet has two
distinctly different amide hydrogen and a-carbon hydrogen environments. The endo amide
hydrogens, labeled Ha in Figure 20, form an inter-strand hydrogen bond to complementary
amide oxygens. The endo a-carbon pro-R position, labeled Hb is sterically congested by a
convergent Hb from the anti-parallel strand. Therefore, only a proton is tolerated in that
position. The exo amide hydrogen, labeled Hc, lacks a specific complementary hydrogen
bond partner and could be replaced without disruption of the two-stranded b-sheet.

Figure 20. Two-stranded b-sheet with different hydrogen environments where endo
hydrogens labeled as Ha and Hb and the exo hydrogens labeled as Hc and Hd.
Doig and co-workers have replaced the Hc like hydrogens of a three-stranded bsheet 35 with methyl groups thereby preventing further H-bond mediated oligomerization
(Figure 21) (Doig, 1997). In addition, negatively charged Asp side chains are located on
both faces of the sheet to introduce intermolecular charge repulsions, which probably
inhibits aggregation.
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Figure 21. Structure of three stranded b-sheet peptide by Doig et al.

Kelly and coworkers showed that selective replacement of two Lys residues in
peptide 36 with N-methyl-Leu residues, prevents high molecular weight b-sheet fibril
formation, which was observed for peptide 36 (Figure 22) (Nesloney, 1996). Peptide 37
represents the first example of a peptidomimetic that adopts a monomeric b-hairpin-like
structure in aqueous buffer.

Figure 22. The first example of a peptidomimetic that adopts a monomeric b-hairpin-like
structure in aqueous buffer reported by Kelly et al.
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1. 4. 5 Covalent Modification of b-Strands by Cyclic Tethers
Further examination of Figure 20 reveals that the exo-a-carbon pro-R position,
labeled Hd, is not sterically congested, so this position can also be substituted without
disruption of the two-stranded b-sheet. Replacement of Hc and Hd with cyclic tethers
should stabilize two-stranded b-sheet model systems as shown in Figure 23. The use of
cyclic tethers are advantageous because they prevent H-bond mediated oligomerizations
and provide additional constraint that stabilizes the extended conformation.

Figure 23. Replacement of Hc and Hd with cyclic tethers.

As can be seen in Figure 20, the ith Hd, and ith+1 Hc are held close to parallel to
each other in the b-sheet or more generally in the extended conformation. The distance
between the ith Hd, and ith+1 Hc bonds is almost perfectly spanned by a puckered 3-carbon
tether. Spanning the ith Hd and ith+1 Hc positions with a 3-carbon tether gives a sixmembered lactam-constrained dipeptide unit. Six-membered lactam-constrained amino
acids as cyclic tethers would be useful since lactams have been shown to provide
conformational constraint in peptides (Figure 24).
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Figure 24. Peptide containing lactam-constrained amino acids as cyclic tethers.

The control of conformation with six-membered rings is well documented. Earliest
examples of five, six and seven-membered lactam-constrained amino acids 40 were
reported by Freidinger and co-workers (Figure 25) (Freidinger, 1982). Six-membered
Figure 25 (Zydowsky, 1988). Moss and co-workers studied a ureido-based inhibitor of
lactam derivatives are glycine-like, lacking an ith+1 amino acid side chain.

These

compounds are reported to give extended conformations where a single peptide unit was
incorporated into the peptide mimetics studied. Zydowsky and co-workers synthesized a,

Figure 25. Examples of lactam-constrained amino acids reported by Freidinger 40,
Zydowsky 41, Moss 42, 43 and their co-workers.

29

a-disubstituted five- and six- membered lactam-constrained amino acids 41 shown in
herpes simplex virus ribonucleotide reductase where the inhibitor contains a lactamconstrained amino acid unit 42 (Moss, 1996). The cyclic compound 42 is reported to be
about 3 times more potent than the acyclic derivative 43 when incorporated into a peptide.
Other groups reported different methods for lactam ring closure (Piro, 1999; Estiarte, 1999;
Griesbeck, 1999; Semple, 1998; Wyss, 1996).
DiPeptideUnit (DPU) 45 and Aza-DiPeptide unit (ADP) 46 shown in Figure 26 are
two constrained dipeptide units designed and synthesized to replace the exo hydrogens of
Hc and Hd with a six-membered ring to lock in the extended conformation, which is
necessary to form b-sheet-like interactions. Importantly, replacement of the pro-R Hd
position to form the six-membered ring requires D-amino acid configuration in order to
better mimic a natural b-sheet. DPU and ADP derivatives are designed to have increasing
levels of constraint. DPU derivatives have one six-membered ring constraint whereas ADP
derivatives have two fused six-membered ring constraints due to the formation of an
intramolecular hydrogen bond provided by incorporation of additional nitrogen in the sixmembered ring. The constraint built in DPU and ADP derivatives which gives rise to
extended structures could be explained better if one considers the constraint built in
individual peptide backbone bonds, which is the reflected in the overall structures of DPU
and ADP derivatives.
Figure 26 shows a definition of the peptide backbone bonds of a dipeptide unit.
Structure 44 is a canonical dipeptide unit shown in the context of a larger dipeptide. There
are five peptide backbone bonds in a dipeptide unit, which are shown in bold and labeled as
DP1-DP5. The double bond character of the DP3 bond insures that either a trans or a cis
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conformation is adopted at that bond; the trans conformation is strongly favored in most
peptides. The unnatural six-membered lactam ring of DPU 45 constraints the DP2 and
DP3 bonds to adopt the extended conformation while maintaining a natural extended
strand-like structure on the lower surface of this view.

The unnatural six-membered

succinylhydrazide ring of ADP 46 adopts the same extended conformation as DPU 45, in
addition, the intramolecular hydrogen bond built into ADP 46 restraints the DP4 and DP5
bonds to adopt the extended conformation while maintaining a natural extended strand-like
structure on the lower surface of this view as in the case of DP2 and DP3.

Figure 26. Structure of a dipeptide unit in the context of a larger peptide 44,
DiPeptideUnit (DPU) 45, Aza-DiPeptide unit (ADP) 45 and the representation of dipeptide
backbone bonds in dipeptides, shown in bold and labeled as DP1-DP5.
DPU and ADP derivatives have a range of conformational constraints, but as
closely as possible they mimic the natural hydrogen-bonding and side chain-side chain
interaction along the bottom face as they are shown in Figure 26. However, the opposite
faces of these dipeptide units are completely unnatural and should completely block
hydrogen-bond mediated oligomerizations, which is a common problem in b-sheet model
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systems. Peptidomimetics formed by incorporation of derivatives of DPU or ADP into
natural amino acid sequences are expected to form extended structures which should
powerfully stabilize b-sheet structures in contrast to peptides made up of only natural
amino acids with relatively higher flexibility. Flexible peptides must lose conformational
entropy to bind to exposed b-sheet surfaces, whereas, constrained peptides can bind with
substantially higher affinity.
DPU and ADP derivatives will be named as DPU(Xxx, Xxx) and ADP(Xxx, Xxx),
in order to describe N- and C-terminal residues. These compounds, where the N-terminal
amino acid has a proton side chain, are analogous to a dipeptide in an extended
conformation with a Gly residue at the N-terminus. In this study, the design and synthesis
of DPU(Gly, Xxx). ADP(Gly, Phe), and the effects of DPU(Gly,Xxx) on b-sheet stability
will be reported.
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CHAPTER 2
RESULTS AND DISCUSSION
2. 1

Synthesis of DPU(Gly, Xxx)
The general structure for DPU derivatives that are synthesized and characterized is

shown in Figure 27. Val, Phe, and Leu derivatives are chosen as the C- terminal amino
acids of the dipeptide since these hydrophobic amino acids occur most frequently in bsheets. Although these are the only derivatives studied, the synthetic route allows the
introduction of any other side chains if needed. When incorporated into peptides along
with other amino acids, these DPU derivatives, having a six-membered ring backbone,
would promote an extended structure in the resulting peptide.

Figure 27. Structures of DPU(Gly, Val) 47a, DPU(Gly, Leu) 47b, and DPU(Gly, Phe) 48.

The overall synthesis of DPU derivatives 47a, 47b, and 48 is shown in Figure 28.
The general idea for the syntheses of Val, Leu and Phe derivatives are the same, the only
difference is that in the reductive amination step Val and Leu moieties are introduced as
tert-Bu esters, whereas the Phe moiety as the methyl ester. This is due to the availability of
the reagents during the synthesis.
Previously described syntheses of lactam-constrained dipeptide amino acids offer
limited possibilities for C-terminal amino acids, low enantiomeric purity and involve
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Figure 28. Synthesis of DPU(Gly, Val) 47a, DPU(Gly, Leu) 47b and DPU(Gly, Phe) 48.
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lengthy and expensive procedures to obtain an aldehyde intermediate 52, which is the key
intermediate for the overall synthesis (Padron, 1998).

One of the most important

achievements in this study was to find a very convenient, easy and inexpensive way to
make lactam-constrained amino acids without any racemization. The first step in the
synthesis is the esterification of D-glutamic acid, 49, with dry allyl alcohol, under argon, in
the presence of trimethylsilylchloride (TMS-Cl, 4.4 equivalents) to yield the diester after 3
days. Triethylamine (TEA, 6.5 equivalents) and Boc anhydride (1.1 equivalents) are added
sequentially and the reaction mixture is stirred overnight. Allyl alcohol is removed under
reduced pressure and the residue is triturated with diethyl ether. Filtration through a celite
pad gives compound 53 in quantitative yield. The product was verified by FAB-MS (328,
M+H+). The appearance of t-butyl and allyl protons and carbons were verified by 1H NMR
and 13C NMR, respectively. The scale of this reaction can be varied greatly (1 gram to 15
grams) with little to no effect on purity or yield.
The next step in the synthesis is to introduce another Boc group to the a-nitrogen of
50. This protection is necessary because the a-nitrogen of 50 is still quite nucleophilic,
especially towards an aldehyde, where the following step will be the reduction of the side
chain ester to an aldehyde. In order to introduce the second Boc-group, compound 50 is
dissolved in anhydrous acetonitrile and added N, N-dimethylaminopyridine (DMAP, 0.2
equivalents) and Boc anhydride (1.1 equivalents). Additional 0.2 equivalents of DMAP
and 0.5 equivalents of Boc anhydride are added after two hours and the reaction is stirred
overnight. Evaporation of acetonitrile and purification by column chromatograph (7:3
hexanes:ethyl acetate) gives 51 in 95% yield. Because compound 51 is UV inactive, the
spots on the TLC (Thin Layer Chromatography) plates could not be seen under UV light.
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After running the TLC, the plates are left in HCl chamber for 10 mins, to remove the Bocgroups on the a-nitrogen, and then immersed into the ninhydrin/ethanol solution. The
plates are then immediately heated by a heat gun, which completes the ninhydrin test where
the primary amines appear as blue-purple spots and the secondary amines as yellow-orange
spots on the TLC plates. Ninhydrin is known to react with amines including a-amino acids
to give colored products. The presence of the product was verified by FAB-MS (428,
M+H+) and a slight change in the chemical shift of the protons and carbons in the Boc
group was observed in 1H and 13C NMR.
The next step in the synthesis is the selective reduction of the diallyl ester to the
semialdehyde 52 with DIBAL-H in ether at -78o C. DIBAL-H is a common reagent used
in the reduction of esters to aldehydes. Reduction of only the side chain ester is needed
since the Val, Leu, or Phe moieties will be introduced to the resulting semialdehyde via
reductive amination reaction.

Martin et al. reported the selective synthesis of the

semialdehyde where they reduced the methyl ester derivative of compound 51 (Padron,
1998).

They achieved the selective reduction to the semialdehyde but the reaction

conditions are highly sensitive to reduction time and the temperature.

Otherwise the

reduction of both ester functions are observed and in addition further reduction takes place
to the corresponding alcohols.
Use of the allyl ester instead of the methyl ester in the semialdehyde synthesis is the
key to the success of this reaction (Oguz, 2001). The use of allyl ester provided high
selectivity in the reaction. The reaction was repeated in increments of 2 min starting from
5 min, and checked for completion by 1H and 13C NMR where the reduction was completed
in 17 min. Martin et al. limited the reduction time to 5 min otherwise reduction of the
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second ester function to the aldehyde was observed. In order to study the extent of the side
chain selectivity for ally ester reduction, the reduction was carried out for 30 min, 1hr, 3
hrs, 5 hrs and over 5 hrs. The extended reaction time has no effect on the selectivity or the
yield. In addition, temperature changes during the reaction period did not cause any over
reduction to the alcohol.

The stability of the aluminum-oxygen complex at this

temperature is the key in the reduction to the aldehyde. Premature release of the aldehyde
as a result of the collapse of the aluminum-oxygen complex will result in reduction to the
alcohol in the presence of hydride. We believe that the allyl ester provides additional steric
hindrance on the main chain ester resulting in exclusive attack of the DIBAL on the sidechain ester. Another modification to the procedure is the equivalents of DIBAL-H used
during the reduction. Martin et al. used 1.1 equivalents of DIBAL-H, where the use of 1.3
equivalents in the case of allyl ester was needed for the completion of this reaction.
As a general procedure for the reduction, compound 51 is dissolved in anhydrous
ether and brought to –78o C. Diisobutyl aluminum hydride (DIBAL-H, 1.0M solution in
hexanes, 1.3 equivalents) is added dropwise at -78º C and the solution was stirred at –78o C
for 30 minutes. The reaction mixture is then quenched with methanol and 10% sodium
bisulfate and extraction with 10% sodium bisulfate yields compound 52, in 98%. The
presence of the product was verified by FAB-MS (372, M+H+) as well as 1H and 13C NMR
where the disappearance of one group of allyl protons and carbons and the appearance of
the characteristic aldehyde proton and carbon was observed.
L-Val, L-Leu

and

L-Phe

were introduced to the semialdehyde via reductive

amination in the presence of sodium triacetoxyborohydride which is shown to be a mild
and a selective reducing agent for aldehydes and ketones (Abdel-Magid, 1996). Compound
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52 is dissolved in anhydrous 1,2-dichloroethane (DCE), and added 1 equivalent of L-ValOtBu·HCl or L-Val-OtBu·HCl or L-Phe-OCH3·HCl followed by sequential addition of
triethylamine (1.1 equivalents) and sodium triacetoxyborohydride (1.4 equivalents). The
reaction mixture is stirred overnight and quenched with saturated sodium bicarbonate. The
phases are separated and the aqueous layer is extracted with ethyl acetate and the DCE
phase is extracted further with saturated sodium bicarbonate. The combined organic layers
are dried, evaporated and purified by column chromatography (4:1 hexanes:ethyl acetate).
Compound 53a or 53b or 56 is obtained in 90%, 89% and 92% yields, respectively.
Reductive amination reaction is scale sensitive and higher yields are obtained when the
reaction is carried out equal to or less than 6 mmoles. The presence of the products was
verified by FAB-MS. In addition, 1H and 13C NMR revealed the presence of the side-chain
methyl groups, and t-butyl ester for 53a and 53b. Appearance of the aromatic, benzylic
and the ester methyl protons and carbons were observed for 56 in 1H and 13C NMR.
The removal of the remaining ester function is needed for the cyclization step. The
hydrolysis of the ester can be done under acidic, basic or metal catalyzed conditions.
Acidic conditions are not useful because Boc- and t-butyl groups on 53 or the Boc-group
on 53 will also be removed. Basic hydrolysis proved to be too slow. The metal catalyzed
alternative was useful and the remaining allyl group was cleanly removed under palladium
catalyzed conditions without any side reactions (Kunz, 1984). Compounds 53 or 56 is
dissolved in anhydrous dichloromethane (DCM) under argon. Morpholine (10 equivalents)
and palladium tetrakistriphenylphosphine (0.1 equivalents) were added sequentially and the
reaction mixture is stirred 30 min. After 30 min, the reaction mixture is extracted with 1N
HCl and the organic layer is then dried and evaporated under reduced pressure. The crude
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product is purified immediately by column chromatography (9:1 CHCl3:MeOH).
Purification should be done immediately after the work-up. The yields are 85%, 83%, 87%
for 54a and 54b and 57, respectively. The presence of the products was verified by FABMS and in addition 1H and 13C NMR spectra verified the absence of the allyl protons and
carbons.
Compounds 54 and 57 are now ready to be cyclized to the corresponding
constrained dipeptide units by intramolecular amide bond formation. Compound 54 is
dissolved

in

anhydrous

acetonitrile

and

diisopropylethylamine (DIEA, 2.1 equivalents).

added

HATU

(1

equivalent)

and

The reaction mixture is stirred under

argon for 2 hrs. At the end of 2 hrs, acetonitrile is evaporated under reduced pressure, the
residue is taken up in DCM and extracted with 10% sodium bisulfate. Evaporation of
DCM layer followed by column chromatography (3:1 hexanes:ethyl acetate) yields
cyclized product 55a, in 77% or 55b, in 76%. The presence of the products was verified by
FAB-MS and 1H and

13

C NMR. X-ray crystal structure of the product 55a was obtained

after crystallization in hexanes (Figure 29).
Instead of HATU, compound 57 was cyclized with PyOAP. PyOAP is less reactive
than HATU, which is believed to prevent any side reactions that HATU may cause and is
active enough for this cyclization. Compound 57 is dissolved in anhydrous acetonitrile and
PyOAP (1 equivalent) is added followed by DIEA (2.1 equivalents) and is stirred overnight
under argon. The product is isolated as in compound 55, which yield 58, 75%. The
presence of the products was verified by FAB-MS and 1H and

13

C NMR. HATU and

PyOAP are both useful for the cyclization steps. The results were very similar in both
cases with no side reactions such as racemization by oxazolone formation, which is a
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common side reaction when the cyclization is carried out with HATU in the presence of a
base.

Figure 29. ORTEP of 55a.

The peptide synthesis via Fmoc chemistry requires amino acids with free carboxyl
ends and Fmoc protected amino groups. In order to prepare the DPU derivatives for
peptide coupling, first the Boc protecting groups and t-butyl ester is removed by treating 55
with approximately 10 mL of 1:1 TFA:DCM mixture, for 15 mins at room temperature.
The excess solvent is removed under reduced pressure followed by high vacuum. The
Fmoc- protecting group is introduced to the dipeptide via Bolin procedure as follows; the
residue after removal of the solvent is dissolved in anhydrous DCM.
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DIEA (4.0

equivalents) is added and the reaction mixture is stirred at room temperature for 30 mins.
TMS-Cl (2 equivalents) is added slowly to the ice cooled reaction mixture, which is then
stirred at room temperature for 2.5 hrs while frequently flushing with argon to remove the
HCl gas produced during the reaction. The reaction mixture is cooled to 0º C again and
Fmoc-Cl (1.0 equivalent) dissolved in DCM is slowly added and stirred overnight at room
temperature. DCM is removed in vacuo followed by addition of 1:1 ether:2.5% Na2CO3
mixture. The phases are separated and the aqueous layer is washed with ether in order to
remove any organic impurities. The water phase is separated and any remaining ether is
evaporated in vacuo. 1N HCl is added till compound 47 precipitates out of solution, pH =
1-2, extracted with ethyl acetate, and the evaporation of ethyl acetate in vacuo gives the
ultimate DPU derivatives 47, ready for coupling in the peptide synthesis, where the yields
are 85% for 47a and 78% for 47b. The presence of the product is verified by FAB-MS. 1H
and 13C NMR spectra verify the removal of the Boc groups and the t-butyl ester. The Fmoc
protecting group is verified by the appearance of aromatic hydrogens and carbons in the
respective spectra.
In the case of DPU derivative 48, after the coupling step, 48 is dissolved in 1:4
MeOH:1N NaOH mixture and stirred overnight at room temperature for the removal of the
methyl ester. MeOH is then evaporated in vacuo, and the resulting residue is dissolved in
water and extracted with ethyl acetate for the removal of any organic impurities present.
The aquous layer is separated and any remaining ethyl acetate is evaporated in vacuo. 1N
HCl is added until compound 48 precipitates out of solution, pH = 1-2, which is then
extracted with ethyl acetate. Removal of ethyl acetate in vacuo yields 48, in 95%. The
presence of the product is verified by FAB-MS. Proton and carbon NMR spectra verify the

41

removal of the methyl group. Dipeptide unit 48, with a free C-terminal, can be used in the
peptide synthesis as the last residue in the peptide. It is possible to synthesize the Fmoc
protected DPU(Gly, Phe) by using PheCOOt-Bu instead of Phe-COOCH3 in the reductive
amination step and following the same procedure that gives compounds 47a and 47b.
2. 1. 1 DPU(Gly, Leu) as a b-Sheet Stabilizing Unit
DPU(Gly, Leu) is incorporated into two peptides and tested as a b-sheet stabilizing
unit. Peptides having a b-sheet structure show a circular dichroism (CD) spectrum with a
negative band near 217 nm (n®p*), a positive band near 195 nm (p®p*), and another band
near 180 nm. The amplitudes of the two long-wavelength bands, their ratios, and the
wavelength of the positive band all show considerable variation with side chains, solvent,
and other environmental factors (Brahms, 1977). This variation of CD parameters is due to
the fact that b-sheets can be antiparallel, parallel, or mixed; intra- or intermolecular; and
are twisted to varying extents. The b-turns have even a wider range of conformations, and
as a result there is no single CD pattern which is characteristic of b-turns (Bandekar, 1982).
Most b-turns give a CD spectra which resembles that of a b-sheet, but shifted 5-10 nm to
longer wavelengths.
Gellman et al. reported a 12-residue peptide 27 with a D-Pro-Gly b-turn unit which
forms a stable, non-aggregating b-sheet structure in 100 mM sodium acetate (NaOAc)
buffer, pH 3.8 (Figure 30) (Stanger, 1998). The amino acid sequence in Gellman's peptide
is H-Arg-Tyr-Val-Glu-Val-D-Pro-Gly-Orn-Lys-Ile-Leu-Gln-NH2. We have reproduced the
CD data for Gellman’s peptide 27 showing a minimum at 217 nm and a maximum at 201
nm for 0.10 mM peptide concentration in 1 mM NaOAc buffer, pH 3.8, at 25 °C. These
bands support a well-defined b-sheet structure. We did temperature studies on Gellman's
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peptide and Figure 31 shows that the peptide secondary structure is stable over an extended
temperature range with a slight increase in b-sheet character at higher temperatures and no
denaturation is observed at any temperature.

Figure 30. Gellman's peptide that forms a stable b-sheet.
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Figure 31. CD-spectrum of Gellman's peptide at various temperatures (0.1 mM peptide in
1 mM NaOAc buffer, pH 3.8, at 25 °C).
We based our peptide designs on that sequence replacing Arg-1, Tyr-2, Ile-10, and
Leu-11 with two DPU 47b. The amino acid sequence of the first peptide synthesized was
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H-DPU 47b-Val-Glu-Val-D-Pro-Gly-Orn-Lys-DPU 47b-Gln-NH2. The DPU 47b moieties
were inserted across from each other where leucine side chains would have a favorable
hydrophobic interaction that would help in the b-sheet stabilization (Figure 32).

Figure 32. General structure of the peptide 59 synthesized as a hybrid of Gellman's
peptide.
The peptide 59 was synthesized on a Milligen 9050 peptide synthesizer on PALPEG-PS solid support. The couplings were done in the presence of Fmoc amino acids (4
equiv.), DIEA (3 equiv.), HATU (4 equiv.), in N,N-dimethylformamide (DMF) and a onehour recycling time. The Fmoc group is removed by the treatment of the resulting peptide
with 2% 1,8-diazobicyclo[4.5.0]undec-7-ene (DBU), 20% piperidine in DMF solution.
The

cleavage

of

the

peptide

from

the

resin

was

done

with

TFA:triisopropylsilane:water:phenol (8.8:0.2:0.5:0.5) (reagent B) for 2 hours. The peptide
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was purified by preparative reverse phase HPLC on a C4 column using a gradient of water
and acetonitrile containing 0.05 % TFA in each solvent. The molecular weight and the
amino acid content of the peptide were verified by MALDI mass spectrometry and amino
acid analysis, respectively.
The HPLC analysis showed 8 peaks and when each fraction is analyzed with mass
spectrometry, all gave the same mass results, which might be the result of racemization of
the DPU 47b during coupling via oxazolone formation (Figure 33). During the synthesis,
the activation of carboxy terminus by converting carboxylic acid OH to a good leaving
group X would lead to oxazolone formation. The oxazolones have tendency to racemize
due to the formation of a resonance stabilized carbanion when the acidic a-proton is
extracted by bases from the chiral center. The proposed mechanism for racemization is
shown in Figure 34. DPU 47b has two chiral centers per dipeptide unit that can racemize.
This would give rise to the formation of 16 possible diastereomers when two DPU’s are
incorporated in the peptide synthesis.

These diastereomers, if they are only minor

constituents in the crude peptide, might be lost during the isolation or the purification of the
peptide but can also accompany the principal peptide through these steps.
CD spectroscopy was used to determine if any secondary structure, especially bsheet structure as in Gellman's peptide, was present. Each fraction (F1-F8) was analyzed at
25 °C in 1 mM aqueous NaOAc buffer, pH 3.8 where the peptide concentration was 0.1
mM. We have observed no well-defined secondary structure of the peptide for fractions 28 (Figure 35). Fractions 3, 6, 7 and 8 possibly have a random coil structure since a random
coil in a peptide exhibits a minimum near 197 nm (p®p*) and a maximum at 217 nm
(n®p*). Fractions 2, 4 and 5 are not recognizable secondary structures. This result is due
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to the fact that the peptides in which the stereochemistry has been inverted (by
racemization) would show little or no structure. Fraction 1 has a minimum at 215 nm,
which is partly a characteristic of a b-sheet structure. Based on this observation we
analyzed it at 5 °C as well since at lower temperatures b-sheet formation might be more
favorable. The CD spectrum shows a greater minima at lower temperatures in line with the
loss of hydrophobic interactions where favorable entropic contributions become the main
driving force for the b-sheet formation of this peptide (Figure 36). We believe that fraction
1 which has some b-sheet character has the correct stereochemistry.

In addition, its

reduced structure compared to 27 is assumed to be as a result of the loss of side chain-side
chain interactions in the DPU peptides.

Figure 32 shows that side chain-side chain

interactions of Arg-1/Gln-12 and Val-3/Ile-10 in peptide 27 no longer exist, instead Gln-12
and Val-3 in peptide 59 each has a cross-strand interaction with a hydrogen from DPU 47b.

Figure 33. HPLC chromatogram of crude peptide 59.
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Figure 34. Proposed mechanism for racemization via oxazolone formation.
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Figure 35. CD spectra of the peptide 59 (0.1 mM peptide in 1 mM NaOAc buffer, pH 3.8,
at 25 °C).
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Figure 36. CD spectra of fraction 1 of the peptide 59 at 5 and 25 °C (0.1 mM peptide in 1
mM NaOAc buffer, pH 3.8).
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In order to test the effects of side chain-side chain interactions for DPU peptides,
we have prepared peptide 63 where only one DPU(Gly, Leu) 47b is incorporated by
replacing Arg-1 and Tyr-2 in peptide 27 (Figure 37). This design is to restore one of the
cross-strand side chain-side chain interactions between Val-3/Ile-10, which does not exist
in peptide 59. The amino acid sequence of peptide 60 is H-DPU(Gly, Leu) 47b-Val-GluVal-D-Pro-Gly-Orn-Lys-Ile-Leu-Gln-NH2 also shown in Figure 37. The synthesis was
carried out under the same coupling conditions as described above for the peptide 59 up to
the DPU(Gly, Leu) 47b coupling step. To avoid racemization, we modified the DPU
coupling step by using a weaker base, collidine, instead of DIEA and adjusting the
coupling temperature to 0 °C for 1 hour and 25°C for an additional 2 hours.
The HPLC results showed 2 peaks having the same molecular weight (Figure 38).
The intensity ratio of fraction 1:fraction 2 is about 40:60 from the HPLC data, which
indicates that the racemization is reduced to a great extent. We analyzed each fraction by
CD at 5 and 25 °C. The second fraction has some b-sheet character and shows increased bsheet character upon heating which is in line with the addition of hydrophobic interactions
in 60 relative to 59 (Figure 39). In general, an increase in b-sheet structure with increasing
temperature is shown to be a consequence of the temperature dependence of the
hydrophobic effect (Urry, 1991; Nesloney, 1996). The first fraction is a 100% random coil
spectrum. This is presumably the fraction having a DPU(Gly, D-Leu), where the favored
stereochemistry would be DPU(Gly, L-Leu). Inverted stereochemistry of the Leu moiety is
as a result of racemization and the appropriate side chain-side chain interactions with Leu11 are no longer possible. The temperature changes have no effect on the CD spectra for
peptide 60 other than a slight change of the molar ellipticity (Figure 40).
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Figure 37. Structure of the peptide 60 shown together with peptides 27 and 59 for an easy
comparison of the peptide structures.
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Figure 38. HPLC chromatogram of crude peptide 60.
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Figure 39. CD spectra of fraction 2 of the peptide 60 at 5 and 25 °C (0.1 mM peptide in 1
mM NaOAc buffer, pH 3.8).
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Figure 40. CD spectra of fraction 1 of peptide 60 at 5 and 25 °C (0.1 mM peptide in 1 mM
NaOAc buffer, pH 3.8).
A careful examination of Gellman’s peptide 27, and the hybrid peptides 59, and 60
in Figure 37 shows that two N- terminal residues Arg and most importantly Tyr in 27 are
replaced with DPU 47b in both hybrid peptides. It is reported that in peptide 27, in
addition to hydrogen bonding interactions between Tyr-2 and Leu-11, long-range side
chain-side chain interactions are also observed between Tyr-2/Leu-11, and Tyr-2/Lys-9.
Hydrogen-bonding and side chain-side chain interactions are expected between Tyr-2/Leu11 since they are across from each other in the folded state of 27. In the flat rendering of
peptide 27 in Figure 37, Tyr-2 and Lys-9 seems to be far apart, but these side chains should
be brought together by a right-handed twist commonly observed for b-sheet peptides. In
order to determine if these favorable interactions are in fact one of the main sources for the
stability of 27, and incorporation of DPU(Gly, Leu) 47b is not the main reason for the
decrease in b-sheet stability, we have synthesized a peptide 61 where we replaced Tyr with
Leu (Figure 41). CD spectrum of peptide 61 is shown in Figure 42.
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61
Figure 41. Structure of the peptide where Tyr-2 in 27 is replaced with Leu in order to
determine the effect of side chain-side chain interactions on the stability of 27.
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Figure 42. CD spectrum of peptide 61 at 25 °C (0.1 mM peptide in 1 mM NaOAc buffer,
pH 3.8).
The overlap of the CD data of all peptides is shown in Figure 43. Comparison of
the CD spectrum of 27 and the CD spectrum of 61 reveals a tremendous decrease in bsheet stability when Tyr is replaced with Leu as a result of loss of b-sheet stabilizing side
chain-side chain interactions. In accordance with this result, it is now possible to make a
more accurate determination for the b-sheet stabilizing effect of DPU(Gly, Leu) 47b by
comparing the peptides 59 and 60 with 61 as opposed to previous comparison made with
27 having Tyr-2 with all the favorable interactions. Leu is a good choice for a replacement
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residue where in all three peptides two Leu residues are across from each other. The
comparison of CD spectra of 60 with 61 in fact reveals that DPU(Gly, Leu) 47b has a
considerable b-sheet stabilizing effect, which is seen from the much greater minima as 230
nm. In addition this stabilizing effect is higher when more DPU residues are incorporated
into the peptides. This can be seen in the CD spectrum of 59, which shows a much greater
minima at 230nm compared to 60. We believe that although there is a loss of side chainside chain interactions to some extent as a result of incorporation of DPU(Gly, Leu) 47b
into peptides, the constraint brought to the peptide structures by DPU(Gly, Leu) 47b results
in extended structures and stabilizes b-sheet structures.
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Figure 43. CD spectra of all peptides.

2. 2 Synthesis of ADP(Gly, Phe) 62
The structure of the target aza-dipeptide ADP(Gly, Phe) 62 is shown in Figure 44.
The six-membered ring backbone and the additional six-membered ring formed as a result
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of the intramolecular hydrogen bonding interactions make this compound highly
constrained and as a result it should have a stronger b-sheet stabilizing effect than
DPU(Gly, Leu) 47b.

Figure 44. Structure of target dipeptide ADP(Gly, Phe).

A general retrosynthetic analysis of this compound shows two possible synthetic
routes to ADP(Gly, Phe) 62 (Figure 45). Both routes require derivatives of D-Asp B and
B¢, which are commercially available and the synthesis of the L-Phe hydrazino derivatives
C or C¢. The first step in Route 1 is coupling of the Nb of C to the side chain carboxyl of
B. The second step is intramolecular cyclization of A by coupling of the Na of the L-Phe
hydrazino moiety to the main chain carboxyl of the D-Asp moiety. In Route 2, coupling
reaction sequences are reversed. The first step in Route 2 is coupling of the Na of C¢ to the
main chain carboxyl of B¢. The second step is intramolecular cyclization by coupling of
the Nb of the L-Phe hydrazino moiety to the side chain carboxyl of D-Asp moiety. A good
start for the synthesis of 62 would be to find a convenient way to make the L-Phe hydrazino
derivative, which is the key intermediate for both routes.
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Figure 45. Retrosynthetic analysis of ADP(Gly, Phe) 62.

2. 2. 1

Synthesis of Hydrazines

In the recent years there has been significant interest in the design and synthesis of
a-hydrazino carboxylic acids for incorporation into peptides due to the structural effects
and biological activity of the derived peptidomimetics. The a-hydrazino carboxylic acids
can be used as inhibitors for various amino acid metabolizing enzymes, and possess
antibiotic activities (Scaman, 1991; Lam, 1988; Viret, 1987). The a-hydrazino carboxylic
acid containing peptidomimetics are metabolically stabilized compared to the natural
peptides of similar structure (Chen, 1992; Morley, 1983). Several methods have been
reported for the preparation of a-hydrazino carboxylic acids, most of which involve
expensive reagents, laborious methods, or harsh reaction conditions. Previously reported
methods for the syntheses of these compounds are; electrophilic aminations with
oxaziridines, rearrangement of hydantoic acids, nucleophilic substitution reactions of a-
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halo carboxylic acids or 2-nosyloxy esters with hydrazine derivatives, or electrophilic Camination of chiral enolates by dialkyl azodicarboxylates (Guy, 1998; Vidal, 1993 & 1997;
Andreae, 1991; Viret, 1987; Shestakov, 1903; Karady, 1971; Gustafsson, 1975; Sawayama,
1976; Hoffman, 1990; Evans, 1988; Gennari, 1986; Trimble, 1986).
We have found a very convenient way to synthesize optically pure a-hydrazino
esters from a-amino esters using inexpensive reagents and in excellent overall yields. The
overall synthesis is shown in Figure 46. Starting from the readily available HCl salt of the
corresponding L-amino acid methyl esters 63, the a-amino group is protected by benzyl
substitution via a two-step reductive amination procedure (Basile, 1994; Abdel-Magid,
1996). The HCl salt of the amino acid 63 is dissolved in dry THF under argon followed by
sequential addition of MgSO4, benzaldehyde (2 equivalents), and TEA (1 equivalent) at 0
ºC.

The reaction mixture is stirred at room temperature overnight.

Filtration and

evaporation of the solvent gives imine 64 along with benzaldehyde. The yield of the
imines 64 increases when excess benzaldehyde is used. After the reaction, removal of
benzaldehyde is not necessary since it does not affect the yield in the reduction step using
excess sodium borohydride (NaBH4). NaBH4 is a common reducing agent for simple
aldehyde and imine reductions.

The imine 64 and excess benzaldehyde mixture are

dissolved in dry MeOH and 4 equivalents of NaBH4 is added. The 4 equivalents NaBH4 is
calculated based on theoretical yield of the imine. This step is very exothermic and for
large scale reactions the best results are obtained by adding NaBH4 in small portions
(0.25g) and waiting for the reaction to settle down before adding any more of the reagent.
NaBH4 is very moisture sensitive so it should be weighed in small portions (0.25 g) at a
time and the reaction mixture is flushed with argon during NaBH4 addition. After all the
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NaBH4 is added, the reaction mixture is stirred for 30 min, which is then quenched with 1N
NaOH and extracted with ether. The ether layer should be extracted at least two times with
brine in order to remove the water retained in the ether. Removal of ether in vacuo gives
65 in 90-95 % overall yield. Sometimes the resulting amine 65 is not pure and contains
unreduced benzaldehyde and benzyl alcohol as the reduction product of benzaldehyde.
When pure amine 65 is needed, column chromatography gives very good results by first
using 1:10 ethyl acetate:hexane mixture until all the unreacted benzaldehyde is eluted, and
then changing the solvent to 1:3 ethyl actetate:hexane to elute the amine 65. The presence
of the imine 64 and the amine 65 derivatives are verified by FAB-MS, 1H and 13C NMR.

Figure 46. Synthesis of a-hydrazino esters from a-amino esters.
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The imines have a distinctive benzylidine proton signal, a singlet around 8 ppm in the 1H
NMR, which disappears after the reduction and gives a diastereotopic set of doublets
around 3.6 and 3.8 ppm.

1

H and

13

C NMR also shows the appearance of a new set of

aromatic protons and carbons for the imines 64.

The imines can have trans or cis

conformations. The b-branched amino acids, Val- and Ile-, strongly favor the trans imine.
Leu- and Phe- also favor trans imine, but Met- gives both cis and trans isomers. Met- has
a complex 1H and 13C NMR due to the overlap of chemical shifts of the two isomers of the
imine, giving sets of multiplets. The methyl protons of -S-CH3 appear at 2.08 and 2.02
ppm for the stereoisomers with approximately the same intensity.
The benzyl protected amino acids are then nitrosated with tert-butylnitrite in
quantitative yields. Amine 65 is dissolved in DCM and cooled to 0° C. Tert-butylnitrite in
DCM is added dropwise and when the addition is completed, the reaction mixture is
refluxed in a 90° C sand bath for 4 hrs. The reaction mixture is cooled to room temperature
and the excess solvent is removed in vacuo, which yields nitrosoamine 66 in quantitative
yield. Nitrosated amino acids form stereoisomers depending on the orientation of oxygen
on the nitrogen that gives a complex 1H and

13

C NMR. Both isomers show similar

multiplicity patterns with different chemical shifts and intensities. The differences in
intensities are considerably higher for Val-, Ile- and Leu-, so the NMR results reported for
these compounds will contain the signals of only the major isomer. For Met-, the 1H NMR
signals of -OCH3 and -SCH3 protons are 3.64, 3.50 and 1.95, 1.80 ppm, respectively, for
the two isomers of 66d. For Phe-, the chemical shifts of -OCH3 protons of the two isomers
of 66e are 3.63 and 3.51 ppm. All the nitrosoamines obtained are very stable compounds.
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The presence of nitrosoamines was verified by FAB MS and the purity of the
nitrosoamines 66 was verified by elemental analysis.
The key to the overall synthesis is the reduction of the nitrosoamines 66 to the
corresponding hydrazines 67.

Previously reported literature procedures for related

reactions gave very little to no yield of the desired hydrazine. In most cases, NMR and
mass spectrometry results showed the formation of the parent amine, as a result of the
cleavage of the N-N bond. We have studied the reduction under the following conditions:
Zn/AcOH/65 °C, Zn/AcOH/RT, Zn/aq. HCl/RT, TiCl3/RT, TiCl3/NH4OAc/RT, Sn/aq.
HCl, Zn/conc. HCl/MeOH/RT, Zn/conc. HCl/MeOH/0 °C and Zn/conc. HCl/MeOH/-78
°C. The reduction with TiCl3, and Sn did not give any hydrazine product ((Lunn, 1984).
The reduction with Zn in aqueous conditions gave some hydrazine product along with the
parent amine. Due to the instability of the hydrazine, the classical purification methods are
not useful to recover the pure hydrazine product. It is crucial for our synthesis to get the
pure hydrazine so that no further purification is needed after work-up.
The best results were obtained with Zn/conc. HCl/MeOH/-78 °C (Oguz, 2002).
There was a significant increase in the hydrazine/amine ratio with Zn/conc. HCl/MeOH in
the order of RT, 0 °C, -78 °C, giving 60/40, 82/18 and 100/0, respectively. At –78 °C, we
obtained the respective hydrazines in very good yield for all the amino esters tried.
Reduction using more dilute HCl is not useful due to solidification of the reaction mixture.
Reduction at low temperatures favors the reduction of the N=O bond over the N-N bond.
The general procedure for Zn/HCl reduction of nitrosoamines is as follows; nitrosoamine
66 is dissolved in dry MeOH under argon. Concentrated HCl is added and then the
reaction mixture is brought to –78 °C. Powdered zinc is added from powder addition
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funnel and the reaction is kept at –78 °C for 3 hrs. At the end of 3 hrs, the reaction mixture
is filtered in order to get rid of excess zinc and solution is made basic by the addition of
cold 6 N KOH with stirring, pH=13-14. The solution is then extracted with cold ether and
the ether layers are extracted at least two times with brine in order to get rid of retained
water in the ether layer. Combined ether layers are dried and evaporated under reduced
pressure, keeping bath temperature below 25 °C. Pure hydrazine 67 is obtained as a yellow
to colorless oil in almost quantitative yields. The work-up step should be done quickly and
it is important to perform FAB MS, 1H and

13

C NMR on the hydrazine immediately after

the work-up due to the high reactivity of the hydrazine. The Nb of the hydrazine is very
nucleophilic, causing oligomer formation due to intermolecular attack of its ester carbon.
The presence of the hydrazine 67 is verified by FAB MS, 1H and 13C NMR. The complex
1

H and

13

C NMR spectra of the nitrosoamine stereoisomeric mixtures are resolved in the

analogous hydrazines. We observed a broad singlet for the Nb protons around 3.2 ppm.
The scheme described here is analogous to the route first by used by Enders and coworkers in their synthesis of RAMP and SAMP (Enders, 1979). The difference being that
they used LAH reduction of their nitrosoamine intermediate, which is not useful in our
synthesis since it would reduce the ester function as well.
In order to make the nitrosation and Zn/HCl reduction quantitative the amino acid
should be protected by an alkyl group on the a-nitrogen. Acyl protecting groups require
stronger nitrosating agents such as NOBF4 and give very low to no yield in the reduction
step. In addition, nitrosoamines of a-amino esters with acyl protecting groups on anitrogen are observed to be unstable and could not be stored over a long period of time
even at low temperatures.
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Powdered zinc readily deteriorates due to oxidation of its surface, therefore,
activation of Zn before the use of HCl/Zn reduction, dramatically increases the efficiency
of the reaction. One way to activate Zn is to wash several times with 5% HCl and to wash
in turn with water, methanol, and ether and then dry under high vacuum.
2. 2. 2 ADP(Gly, Phe) Synthesis: Route 1
The detailed retrosynthetic analysis for the synthesis of ADP(Gly, Phe) 70 from Route 1 is
shown in Figure 47. The analysis of 70 shows that for selective deprotection of C- and Nterminals of the ultimate aza-dipeptide 70, P1 should be orthogonal to P2. It is possible to
get target dipeptide 70 by intramolecular cyclization of 69 after the removal of the
protecting groups P3 and P4. It would be advantageous to have P3 and P4 the same so that
they can be removed in one step. As a result, for 69 to be a useful intermediate, P1 and P2
should be orthogonal to each other as well as to P3 and P4. 69 can be synthesized by
coupling the Nb of 67e, to the side chain carboxyl of the D-Asp derivative 68. 67e has a
benzyl group as P4, which would make P3 also a benzyl group and both can be removed by
catalytic hydrogenation in one step. 67e has a methyl ester as P1, which can be removed
under basic conditions. P2 as a Boc-would be the best choice since the Boc group is
easy to introduce, easy to remove and very stable under basic conditions and catalytic

Figure 47. Detailed retrosynthetic analysis of ADP(Gly, Phe).
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hydrogenation.

D-Asp

derivative 71 with its main chain carboxyl group benzyl protected

and its amino group Boc-protected would be an ideal starting material for this synthesis.
The forward synthesis with appropriate starting materials is shown in Figure 48. In
the first step, Boc-D-AspCOOBn 68 (1 equivalent) is dissolved in dry DCM under argon,
and PyOAP (1 equivalent) and TEA (1.1 equivalents) are added and cooled to 0° C. A
solution of 67e in dry DCM is added to the reaction mixture through an addition funnel.
The reaction mixture is stirred at 0° C for 30 min and at room temperature overnight. The
DCM phase is extracted with cold water and brine, dried and the solvent was removed in
vacuo. The product is purified by column chromatography (3:1 hexanes:ethyl acetate).
Compound 69 is obtained as a white solid in 85% yield. The presence of product is
verified by FAB MS (590, M+H+) (490, M-Boc+H+), 1H, and

13

C NMR. Compound 69

has a complex 1H NMR spectrum, which is probably due to the many conformational
possibilities of 69 providing different chemical environments for the protons and the
carbons. The tert-butyl protons do not have the characteristic sharp singlet but appear as 3
sharp singlets with different ratios. A slight downfield shift of around 0.02-0.03 ppm is
observed for the methyl ester protons, which also appear as 3 sharp singlets with different
ratios. A larger downfield shift is observed for the aromatic protons.
In order to prepare compound 69 for cyclization, it is necessary to remove the
benzyl ester and the benzyl group on Na. Compound 69 is dissolved in the minimum
amount of EtOH, a catalytic amount of 10% Pd/C is added and hydrogenated at 50 psi in a
Paar Hydrogenator for 2 hrs. The reaction mixture is filtered through a celite cake, and
evaporation of EtOH gives compound 71 in 100% yield. Hydrogenation is a very clean
and mild method for the removal of benzyl groups in quantitative yield. Pd catalyzed
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hydrogenations, especially the removal of benzyl groups on nitrogen, are generally carried
out in the presence of a trace amount of acid such as AcOH or HCl. Removal of benzyl
group gives an amine, which coordinates to active Pd and poisons the catalyst. In the
presence of acid, free amine gets protonated and does not coordinate to Pd. Due to

Figure 48. Synthetic route 1 for the synthesis of ADP(Gly, Phe).

the presence of the Boc- group, strong acid cannot be used in our reaction because the Bocgroup will also be removed. In fact in our reaction, hydrogenation of 69 does not require
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any external acid source because removal of the benzyl ester provides free carboxylic acid
functionality, which is acidic enough for this reaction and not strong enough to remove the
Boc- group. The presence of the compound 71 is verified by FAB MS (409, M+H+), (309,
M-Boc+H+) and the disappearance of two sets of aromatic protons and carbons are
observed in the 1H and 13C NMR spectra, respectively.
After the removal of the benzyl groups, compound 71 is ready to be cyclized to the
corresponding aza-dipeptide by intramolecular amide bond formation. Compound 71 has
two nucleophilic hydrogens and the coupling of Na to the free carboxyl group, would give
the desired six-membered ring 70, which is the thermodynamic product.

Whereas,

coupling of the Nb to free carboxyl group would give five-membered ring 72, which is the
kinetic product.

Although the five-membered ring forms faster, Nb being an amide

nitrogen is much less nucleophilic than Na, so in theory, the only product from this
coupling should be the desired six membered ring 70. Compound 71 is dissolved in dry
acetonitrile at room temperature, PyOAP (1 equivalent) and DIEA (2.1 equivalents) is
added. The reaction mixture is stirred at room temperature overnight. Acetonitrile is
removed in vacuo, the residue is dissolved in DCM, and extracted with 10% NaHSO4.
DCM is removed in vacuo and the product is purified by column chromatography (3:1
hexanes:ethyl acetate). The product obtained is a white solid and at this point it is not
possible to verify if the product is the six-membered ring 70 or the five-membered ring 72.
These two compounds are constitutional isomers having the same empirical formula, which
makes it impossible to verify the product by either FAB MS (392, M+H+) or by elemental
analysis. The complex 1H and
cyclization product.

1

13

C NMR spectra of 69 are resolved in the analogous

H NMR shows the characteristic sharp singlet at 1.41 ppm for tert-
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butyl protons, a sharp singlet at 3.64 ppm for methyl ester protons, and two doublets
between 5-6 ppm, which is a characteristic shift for a proton on nitrogen when the nitrogen
is neighboring an electron deficient atom such as a carbonyl carbon. One of the doublets
belongs to the proton on the N-terminal nitrogen, which couples to the neighboring proton
on the a-carbon. Although 70 and 72 are structural isomers, their structures are very
similar which makes the splitting pattern of each compound exactly the same if analyzed
by 1-D 1H and 13C NMR, excluding the Na and Nb protons. In theory, in 70, the proton on
Nb should give a singlet since there are no neighboring hydrogens, and in 72, the proton on
Na should couple to the hydrogen of the a-carbon of Phe moiety and should give a doublet.
Although the 1H NMR spectrum is consistent with the five-membered ring structure 72, it
is not possible to make accurate predictions from these results for the structure of the
compound since N-H hydrogens can show different shifts and splitting patterns depending
on their chemical environment and interactions with the solvent. One way of absolutely
accurate characterization was to get a crystal structure of the compound. We tried to
crystallize the compound in many different solvent systems, but 70/72 is not a crystalline
compound and comes out from the most solvents as an oil. One way to get a crystalline
compound would be to remove the Boc- group from the N-terminal and to introduce a
more rigid protecting group such as the para-nitrobenzylsulfonyl (pNBS-) group (Figure
49) (Reichwein, 2000). Boc-group is removed by treating compound 70/72 with 4M HCldioxane at 0° C for 8 hrs. The solvent is removed in vacuo. The residue is dissolved in dry
DCM and para-nitrobenzylsulfonyl chloride (pNBS-Cl, 1.1 equivalents) is added followed
by TEA (1.0 equivalent). After stirring two days, the solution is extracted with 2N HCl,
1N NaHCO3, and brine, dried and concentrated in vacuo.
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Purification by column

chromatography (1:1 hexanes:ethyl acetate) gives pNBS-protected 70/72 as a yellow solid
in 88% yield.

The product is easily crystallized from DCM/hexanes and the crystal

structure verifies the presence of five-membered ring 73 as the product (Figure 50).
Since 72 is the only product from Route 1, and no formation of the six-membered
ring 70 is observed, it is possible to say that although Nb is a much weaker nucleophile than
Na, it is still nucleophilic enough to give the kinetic product as the only product.
Generally, thermodynamic product formation would be favored by heating the reaction
mixture but the rate of the five-membered ring formation is several orders of magnitude
faster than the six-membered ring, which makes the thermal control of the product very
difficult. One way to avoid five-membered ring formation over six-membered ring is to
protect the amide nitrogen, Nb, of 69 before the hydrogenation step, which would diminish

Figure 49. Protection of the N-terminal nitrogen of 70/72 with pNBS in order to get a
more crystalline product.
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Figure 50. ORTEP of 73.

its already low nucleophilicity (Figure 51). The easiest way is to introduce a Boc- group to
the Nb, which would leave Na as the only nucleophile, and make the six-membered ring as
the only likely cyclization product. The N-terminal nitrogen and Nb will show similar
reactivity during Boc- protection and both will react with t-Boc2O. To insure that Nb will
be Boc- derivatized, the reaction conditions should also favor the diBoc- protection of the
N- terminal nitrogen. Compound 69 is dissolved in dry acetonitrile and DMAP (0.4
equivalents) and t-Boc2O (2.2 equivalents) are added. An additional 0.4 equivalents of
DMAP and 2.2 equivalents of t-Boc2O are added after two hours and the reaction is stirred
overnight. Evaporation of acetonitrile and purification by column chromatograph (3:1
hexanes:ethyl acetate) gives 74 in 88% yield. The presence of the compound is verified by
1

H and 13C NMR. 1H NMR shows two singlets at 1.48 ppm and 1.46 ppm for two different
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sets of tert-butyl protons and a sharp singlet for methyl proton at 3.54 ppm. These methyl
protons appeared as three sharp singlets for compound 69. The resolution of the spectrum
is probably due to the addition of bulky Boc- groups that hinders the flexibility of
compound 74, which adopts one stable conformation and gives a more resolved spectrum.
Compound 74 having its Nb protected, is hydrogenated and isolated as described earlier.
1

H NMR shows that the product has lost one set of Boc-group either during hydrogenation

or during the work-up step. It is known that when there are two Boc- groups on the same
nitrogen, one Boc-group can easily be lost probably due to electronic effects. Based on this
fact, we have assumed the Boc-group on the N-terminal nitrogen is lost which would give
compound 76. Compound 76 with a protected Nb protected would still give six-membered
ring 78. Coupling in the presence of PyOAP and DIEA followed by removal of the Bocgroups, and protection with p-NBS- as described earlier, gave yellow crystals, and the
crystal structure verifies the presence of five-membered ring 73. This shows that Bocgroup on Nb was lost which makes 75 and 77 the right intermediate products. The Bocgroup on Nb, might be very labile to heat and during the evaporation of EtOH which needs
warmer bath temperatures would come off easily. In order to overcome this problem, we
have used MeOH, which has a lower boiling than EtOH in the hydrogenation step and
evaporated the solvent after the reaction in colder bath temperatures (Figure 52). 1H NMR
shows three sets of tert-butyl protons, which verifies the presence of all three Boc- groups.
Cyclization of the fully protected compound 79 with PyOAP and DIEA in acetonitrile gave
a product, which has identical 1H and

13

C NMR spectra with compound 77, which was

obtained from the previous cyclization reactions prior to p-NBS- protection. The 1H NMR
spectrum shows two sets of tert-butyl protons, which indicates that although the cyclization
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Figure 51. Protection of Nb of 69 to reduce its nucleophilicity.

69

reaction is started with the Nb protected, during the reaction, the Boc-group on the Nb
comes off to give the five-membered ring 77 as the only product. As a conclusion, it is not
possible to get the desired six-membered ring from Route 1.One solution might be to
protect Nb with an alkyl protecting group which would not be as labile as Boc- group. The
problem with that is that there are not many good choices for alkyl protecting groups for
nitrogen. Benzyl, allyl, and triphenylmethyl (trityl) are amongst the best alkyl protecting
groups but Na is already benzyl protected. Nb should have an orthogonal protecting group
to Na and trityl and allyl groups are not stable to hydrogenation and would also be removed
during the hydrogenation step. Another solution would be to change the overall synthesis
and use a different set of protecting groups. This also has limitations for instance benzyl is

Figure 52. Hydrogenation of 74 in MeOH and cyclization of fully protected 79.
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the best choice for Na because it makes the nitrosoamine and hydrazine synthesis
quantitative. Methyl ester is also a good choice for hydrazine 67e because it is only labile
to base and survives duringHCl/Zn reduction whereas an acid labile protecting group might
be removed during the reduction. It was not possible to find another set of protecting
groups, that would make it possible to get the desired six-membered aza-dipeptide.
2. 2. 3 ADP(Gly, Phe) 81 Synthesis: Route 2
The detailed retrosynthetic analysis for the synthesis of ADP(Gly, Phe) 81 from
Route 2 is shown in Figure 53. Unlike Route 1, Route 2 does not have any intermediate
compounds with the possibility of giving five-membered ring. In other words, formation
of five-membered ring from this route is not possible, and the only product should be the
desired six-membered aza-dipeptide 81.

For the selective deprotection of C- and N-

terminals of the ultimate aza-dipeptide 81, P1 should be orthogonal to P2. It is possible to
get the target dipeptide 81 by intramolecular cyclization of 82 after the removal of the
protecting groups P3 and P4. It would be advantageous to have P3 and P4 the same so that
they can be removed in one step, and orthogonal to P1 and P2. 82 can be synthesized by
coupling the Na of 84 after the removal of P5 to the main chain carboxyl of 83. For the
selective removal of P5 over P4 these groups should be orthogonal. For this coupling to be
selective for Na over Nb, a good strategy would be to put a bulky acyl-protecting group on
Nb of 84. This would decrease its nucleophilicity to a great extent, which would make Na
attack more favorable in the coupling step. The Boc- group, being one of the bulkiest acylprotecting group, would be the best choice. Assigning P4 to be Boc-, an excellent choice
for P3 would be tert-butyl since they both would be removed easily under acidic conditions
before cyclization. 84 can be obtained by protecting Nb of readily available hydrazino L-
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Phe 67e with a Boc- group. As an amino protecting group, benzyloxycarbonyl (Cbz)
would be a good choice for the

D-Asp

derivative 83, which can be removed by

hydrogenolysis and is orthogonal to Boc and methyl ester. Coupling of 83 and 84 might be
the most challenging step because the Na of 84 is a sterically hindred secondary nitrogen
which will be coupled to the more sterically demanding main chain of the D-Asp derivative
83 compared to its side chain.

Figure 53. Detailed retrosynthetic analysis of ADP(Gly, Phe).

The forward route for the synthesis of ADP(Gly, Phe) 81 with the appropriate
reagents is shown in Figure 54. The first step in the synthesis is the protection of Nb with
Boc- group. Compound 67a is dissolved in DCM and t-Boc2O (1.1 equivalents) is added
and the reaction mixture is stirred at room temperature overnight. DCM is removed in
vacuo and purification by column chromatography gave 85 with a very low yield, 10%.
The yield was increased by adding solid t-Boc2O (1.1 equivalents) directly to 67e,
as an oil, and they were stirred together at room temperature for 30 min without any
solvent present (Mäeorg, 1996). The t-Boc2O melts at room temperature easily and the
mixture becomes homogenous. After 30 min, a very small amount of acetonitrile is added
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and the reaction is stirred overnight. Acetonitrile is removed in vacuo and the protected
hydrazine 85 is isolated by column chromatography (4:1 hexanes:ethyl acetate) in 86%
yield along with some unreacted hydrazine. The presence of the product is verified by
FAB MS, 1H and 13C NMR. 1H NMR shows the disappearance of the broad singlet for the
Nb protons around 3.2 ppm of 67e, and the appearance of a singlet at 1.35 ppm for tertbutyl protons and a broad singlet around 6.8 ppm for the Nb proton.

Figure 54. Synthetic route 2 for the synthesis of ADP(Gly, Phe).

To prepare compound 85 for coupling, the benzyl group on Na is removed by
hydrogenolysis. Compound 85 is dissolved in MeOH, a catalytic amount of 10% Pd/C is
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added and hydrogenated at 45 psi in a Paar Hydrogenator for 3 hrs. The reaction mixture is
filtered through a celite cake, and evaporation of the MeOH gives compound 86 in 100%
yield. Acid cannot be used during the hydrogenolysis due to the presence of the Bocgroup, which will also be removed. For large-scale reactions, the amine product would
poison the catalyst, and it might be necessary to add additional Pd/C during the reaction.
The presence of product is verified by 1H and 13C NMR. A downfield shift is observed for
the tert-butyl and methyl ester protons and carbons in 1H and

13

C NMR spectra,

respectively. In addition, the 1H NMR shows the appearance of a new broad triplet at 4.24
ppm for the Na proton.
The next step in Route 2 also had to be optimized. In general, coupling reactions of
sterically hindred amino acid derivatives give very low to no yield and require harsh
conditions. The hydrazino L-Phe derivative 86 has significant steric bulk and coupling
with conventional coupling agents such as HATU and PyOAP would not be useful for this
step. Acid chloride activation is one method used in difficult couplings but this method
was not considered for our reaction because of harsh conditions required for its formation
and due to possible racemization. The best methods developed for the mild and efficient
couplings of sterically hindered residues are the acid fluoride method and the symmetrical
anhydride method. Both of these methods have many advantages, such as their ability to
react in high yield with reduced oxazolone formation in the presence of tertiary bases, and
they afford efficient coupling even in the absence of a base.
The first method used for this coupling was the acid fluoride method (Figure 55). In this
method, the acid fluoride of the corresponding amino acid with the free carboxyl end is
formed which is then coupled to the amino acid with the free amino end.
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Cbz-D-

Asp(COOt-Bu)COOH 87 is dissolved in dry DCM and pyridine (1.75 equivalents) and
cyanuric fluoride (2.25 equivalents) are added at 0 °C. The solution is warmed to room
temperature and stirred at room temperature for 3 hrs, and then crushed ice along with
additional DCM is added. The organic phase is separated, washed with ice-cold water,
dried and the solvent is removed in vacuo. Cbz-D-Asp(COOt-Bu)COF 94 was obtained as
a colorless oil in 77% yield.

13

C NMR for 87 shows the main chain carboxylic acid carbon

at 175.13 ppm. In the acid fluoride, this carbon splits into a doublet at 164.22 ppm and
158.36 ppm as a result of the spin-spin coupling with fluoride. The activated carboxylic
acid is now ready for coupling. Compound 94 (10 equivalents) is dissolved in DCM and
86 is added followed by DIEA (5 equivalents). After stirring overnight, the reaction
mixture was washed with brine and dried.

The compounds separated by column

chromatography are analyzed and none of them were the desired compound 88.

Figure 55. Acid fluoride method.

The second coupling method used was symmetrical anhydride method (Fu, 2002;
Jensen, 1998) (Figure 56). Symmetrical anhydride formation is a condensation reaction
where two equivalents of the amino acid with the free carboxyl end is reacted with 1
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equivalent of N,N¢- dicyclohexylcarbodiimide (DCC) 95, which results in the formation of
an anhydride linkage. In order to prepare the anhydride 96, Cbz-D-Asp(COOt-Bu)COOH
87 (2 equivalents) is dissolved in the minimum amount of dry DCM and DCC 95 (1
equivalent) is added under argon. Immediately after the addition of DCC, insoluble N, N¢dicyclohexylurea (DCU) precipitates as a white solid. The mixture is stirred at room
temperature for 30 min and the solid DCU removed via suction filtration.

DCM is

removed in vacuo with a bath temperature kept below 25° C. The resulting anhydride 96 is
used immediately after isolation, otherwise decomposition is observed on standing for a
longer period of time. The extent of reaction can be followed by TLC (9:1 CHCl3:MeOH)
and the formation of product can also be verified by 1H and

13

C NMR. A significant up

field shift around 10 ppm is observed for the main chain carbonyl carbon of 96 in the 13C
NMR spectrum. Compound 86 is dissolved in the minimum amount of dry DCM under
argon and added to the semi-solid anhydride 96. More DCM is added dropwise by a
syringe until everything goes into solution. It is important to have a very concentrated
solution mixture to optimize the efficiency of the reaction. After everything goes into
solution the mixture is stirred at room temperature until the reaction is completed, the
extent of the reaction is followed by 1H NMR. DCM is removed and the product is
purified by column chromatography (3:1 hexanes:ethyl acetate). The coupling reaction
was studied under the following conditions (equivalents of anhydride used/reaction time): 5
equiv/16 hrs, 1 equiv/16 hrs, 2 equiv/24 hrs, 2 equiv/2x24 hrs, 2 equiv/3x24 hrs. Under the
reaction conditions, 5 equiv/24 hrs gave the desired product as the major product but 1H
and 13C NMR spectra showed extra signals having the same chemical shifts as the protons
and carbons of the starting material 86. The presence of the unreacted starting material was
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Figure 56. Symmetrical anhydride method.

not seen on TLC plates where only one spot was present. Since the results of 1H and 13C
NMR spectra verifies the presence of unreacted starting material 86 we have tried many
different solvent systems in order to get a separation on TLC plates and no separation was
observed in any of these conditions. The polarities of 86 and 88 are quite different and
there should be a separation if they would act as two different molecules. An explanation
for the TLC results could be the formation of a non-covalent interaction between 86 and 88
such as hydrogen bonding, which might make these two separate molecules act as one. As
a result it is not possible to purify 88 by traditional purification methods. The reaction
conditions were optimized to make the reaction go to completion without any remaining

77

unreacted 86. The reaction conditions studied gave the following 88/86 ratios: (5 equiv/16
hrs, 1 equiv/16 hrs, 2 equiv/24 hrs, 2 equiv/2x24 hrs, 2 equiv/3x24 hrs); (1.00/0.47,
1.00/0.47, 1.00/0.185, 1.00/0.02, 1.00/0.00), respectively. To our surprise, the extended
reaction times had more significant effect on the yield than the equivalents of the anhydride
used. Same 88/86 ratios are obtained for 5 equivalents and 1 equivalent of the anhydride
used and this ratio was increased significantly when the reaction time is doubled. 1H NMR
spectrum is not well resolved probably because of the many different conformation
possibilities for compound 88. The tert-butyl protons for the Boc-group and tert-butyl
ester have different chemical signals and show two singlets at 1.38 ppm and 1.46 ppm.
The methyl ester protons show a singlet with double peaks, probably due to different
chemical environments.
Although acid fluorides are generally believed to be more reactive than symmetrical
anhydrides, the symmetrical anhydride method is much more efficient at acylating the
sterically hindred 86. For the reactions with symmetrical anhydrides, the best results are
obtained in nonpolar solvents such as DCM. One possibility is that the symmetrical
anhydride may possess an enhanced reactivity in the aprotic nonpolar solvent for which
anchimeric assistance from hydrogen bonding is more pronounced (Figure 57).

Figure 57. Anchimeric assistance provided by the hydrogen bond donation of the
symmetrical anydride.
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The next step in the synthesis is the removal of tert-butyl groups. The most
common two reagents for this reaction is 4M HCl-dioxane solution and TFA:DCM (1:1)
mixture. 4M HCl-dioxane might be a better reagent for this reaction because TFA from the
TFA salt of compound 89 might also get activated in the cyclization step and might react
with the free Nb of 89 faster than the side chain carboxyl of 89. For the deprotection of 88,
4M HCl-dioxane solution is added to 88 at 0 °C and the reaction is stirred at this
temperature for three days or until the reaction is completed. The solvent is removed in
vacuo and the resulting HCl salt of 89 is used without any purification in the cyclization
step. The absence of tert-butyl protons and carbons is verified by 1H and

13

C NMR,

respectively. This is an unusually slow reaction because in general the deprotection with
this reagent is completed in less than 2 hrs. We also tried TFA:DCM mixture for the
removal of tert-butyl groups of 88. Compound 88 is added to a TFA:DCM (1:1) mixture at
0 °C and stirred at this temperature for 2 hrs. The solvent is removed in vacuo, left under
vacuum overnight to remove excess TFA and the resulting TFA salt of 89 is used without
any purification in the cyclization step. The absence of tert-butyl protons and carbons is
verified by 1H and 13C NMR, respectively.
The same cyclization procedure is used for the HCl or the TFA salts of 89. The
residue 89 from the deprotection step is dissolved in dry acetonitrile and PyOAP (1
equivalent) is added followed by DIEA (2 equivalents). The reaction mixture is stirred at
room temperature overnight. Acetonitrile is removed in vacuo and the cyclization product
90 is isolated by column chromatography (1:1 hexanes:ethyl acetate) in very low yield,
10%. The presence of product is verified by 1H and

13

C NMR. The overlapping broad

multiplets observed for compound 88 are resolved into sharper well-resolved multiplets in
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the 1H NMR spectrum. The 1H NMR shows two amide nitrogens of 90 between 5-6 ppm.
The low yield of the compound was explained when another compound was isolated by
column chromatography.

1

H NMR spectrum of the side product shows two broad signals

at 3.26 ppm and 1.95 ppm with very high intensity, which most likely are pyrrolidine
protons of PyOAP, and the rest of the spectrum is compatible with a compound having a
similar splitting pattern as for 89. The mechanism of the side product formation or the
structure of the side product is not yet known but we will try different activating agents and
coupling conditions to get the desired product in high yields.
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CHAPTER 3
EXPERIMENTAL
3. 1

Diallyl (2R)-2-[(tert-butoxycarbonyl)amino]pentanedioate (50)

To an ice cold stirred suspension of D-glutamic acid (49) (6.24 g, 34 mmol) in dry
allyl alcohol (150 mL) was slowly added TMS-Cl (17.3 mL, 136 mmol, 4.4 equiv.). After
the addition was completed, the ice bath was removed and the reaction was stirred at room
temperature for three days. Triethylamine (31 mL, 221 mmol, 6.5 equiv.) and Boc2O (8.2
g, 37.4 mmol, 1.1 equiv.) were added sequentially and the reaction mixture was stirred
overnight. The solvent was removed under reduced pressure, the residue triturated with
ethyl ether and filtered through a Celite pad. The solvent was evaporated yielding a yellow
oil as the pure product (11.1 g, 100%). 1H NMR (250 MHz, CDCl3) d 1.43 (s, 9H), 1.99
(m, 2H), 2.19 (m, 2H), 2.47 (m, 1H), 4.58 (d, 2H), 4.63 (d, 2H), 5.29 (m, 4H), 5.55 (d, 1H),
5.90 (m, 1H), 5.92 (m, 1H).

13

C NMR (62.5 MHz, CDCl3) d 27.19, 28.03, 30.01, 52.76,

64.95, 65.58, 79.41, 117.92, 118.38, 131.48, 131.94, 155.24, 171.66, 172.03. FAB-MS
328 (M+H)+.
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3. 2

Diallyl (2R)-2-N,N-[bis (tert-butoxycarbonyl)amino]-pentanedioate (51)

To a stirred solution of 50 (5 g, 15.3 mmol) and DMAP (379 mg, 3.1 mmol, 0.2
equiv.) in dry acetonitrile (50 mL) was added Boc2O (3.67 g, 16.8 mmol, 1.1 equiv.) at
room temperature. After two hours, an additional 1.35 g Boc2O and 379 mg DMAP were
added and the red solution was allowed to stir overnight. The solvent was removed under
reduced pressure and the residue was taken up in hexanes/ethyl acetate (7:3). The crude
product was purified by flash column chromatography to yield the pure product as a yellow
oil (6.17 g, 95%). 1H NMR (250 MHz, CDCl3) d 1.49 (s, 18H), 2.20 (m, 2H), 2.45 (t, 1H),
2.50 (m, 2H), 4.58 (d, 2H), 4.61 (d, 2H), 5.28 (m, 4H), 5.88 (m, 1H), 5.93 (m, 1H).

13

C

NMR (62.5 MHz, CDCl3) d 25.05, 28.08, 30.86, 57.52, 65.34, 65.88, 83.43, 118.27,
118.33, 131.86, 132.31, 152.11, 170.15, 172.44. FAB-MS 428 (M+H)+. anal. calcd for
C21H33NO8(%): C 59.02, H 7.73, N 3.28. Found: C 59.18, H 7.70, N, 3.45.
3.3

Allyl (2R)-2-N,N-[bis (tert-butoxycarbonyl)-amino]-5-oxopentanoate (52)
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A solution of 51 (1 g, 2.34 mmol) in dry Et2O was cooled to -78º C. DIBAL (3.51
mL, 1.0 M in hexanes, 3.51 mmol, 1.5 equiv.) was slowly added over 10 minutes. The
reaction was stirred for 30 minutes after the addition was completed and quenched with
methanol (4 mL) and 10% NaHSO4 (2 mL). The mixture was stirred at room temperature
for 30 minutes then extracted with 10% NaHSO4 and the solvent was evaporated to yield
the product as a yellow oil (0.84 g, 98%).

1

H NMR (200 MHz, CDCl3) d 1.49 (s, 18H),

2.18 (m, 2H), 2.54 (m, 2H), 2.56 (t, 1H), 4.62 (m, 2H), 4.91 (m, 1H), 5.27 (m, 2H), 9.78 (t,
1H).

13

C NMR (50 MHz, CDCl3) d 22.45, 28.09, 40.61, 57.55, 65.93, 83.57, 118.34,

131.84, 152.16, 170.07, 201.01. FAB-MS 372 (M+H)+.
3. 4

Typical Experimental Procedure for Reductive Amination (53/56)

Compound 52 (0.761 g, 2.1 mmol) and the HCl salt of the corresponding amino
acid ester (2.1 mmol, 1 equiv.) were dissolved in dry DCE (10 mL) under argon. TEA
(0.30 mL, 2.3 mmol, 1.1 equiv.) was added followed by sodium triacetoxyborohydride
(0.61 g, 2.94 mmol, 1.4 equiv.). The mixture was stirred overnight then washed twice with
saturated NaHCO3 (30 mL). The organic layer was dried over Na2SO4 and evaporated.
The residue was taken up in hexanes:ethyl acetate (4:1) and purified by flash column
chromatography to yield 53/56, as a yellow oil in 89-92%.
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Tert-butyl
(2S)-2-N-1-[(5-allylcarboxylate)-(4R)-bis(N´,
N´-tert1
butoxycarbonylamino)pentyl]-2-amino-3-methyl-butanoate (53a) H NMR (250 MHz,
CDCl3) d 0.92 (d, 6H), 1.47 (s, 9H), 1.49 (s, 18H), 2.10 (m, 7H), 2.45 (t, 1H), 2.80 (d, 1H),
4.60 (d, 2H), 4.62 (m, 1H), 5.27 (m, 2H), 5.90 (m, 1H). 13C NMR (62.5 MHz, CDCl3) d
18.92, 19.31, 27.21, 27.56, 28.13, 28.33, 31.84, 48.25, 58.29, 65.72, 68.08, 80.86, 83.11,
119.09, 132.03, 152.31, 170.71, 174.82. FAB-MS 529 (M+H)+. Anal. calcd for
C27H48N2O8: C, 59.34; H, 9.16; N, 5.13. Found: C, 59.34, H, 8.76; N, 5.05.
Tert-butyl
(2S)-2-N-1-[(5-allylcarboxylate)-(4R)-bis(N´,
N´-tertbutyloxycarbonylamino)pentyl]-2-amino-4-methyl-pentanoate (53b) 1H NMR (250
MHz, CDCl3) d 0.90 (m, 6H), 1.35-1.50 (m, 31H), 1.72 (m, 1H), 1.95 (m, 1H), 2.14 (m,
1H), 2.46 (m, 1H), 2.60 (m, 1H), 3.10 (t, 1H), 4.60 (m, 2H), 4.88 (m, 1H), 5.25 (m, 2H),
5.88 (m, 1H). 13C NMR (62.5 MHz, CDCl3) d 22.81, 22.86, 25.18, 27.28, 27.66, 28.21,
28.36, 43.25, 47.83, 58.32, 60.89, 65.77, 80.88, 83.11, 118.13, 132.15, 152.40, 170.69,
175.69. FAB-MS 543 (M+H)+.
Methyl
(2S)-2-N-1-[(5-allylcarboxylate)-(4R)-bis(N´,
N´-tert1
H NMR (250
butyloxycarbonylamino)pentyl]-2-amino-3-phenyl-propanoate (56)
MHz, CDCl3) d 1.48 (m, 18H), 1.89 (m, 1H), 2.09 (m, 1H), 2.47 (m, 1H), 2.61 (m, 1H),
2.92 (d, 2H), 3.49 (t, 1H), 3.62 (s, 3H), 4.59 (m, 2H), 4.83 (dd, 1H), 5.26 (m, 2H), 5.87 (m,
1H), 7.20 (m, 5H). 13C NMR (250 MHz, CDCl3) d 26.69, 27.17, 27.83, 39.58, 47.53,
51.40, 57.88, 62.91, 65.45, 82.85, 117.84, 126.52, 128.24, 128.96, 131.73, 137.13, 152.02,
170.30, 174.89. FAB-MS 535 (M+H)+. anal. calcd for C28H42N2O8 (%): C 62.90, H, 7.92,
N 5.24. Found: C 62.78, H 7.75, N, 5.22.
3. 5 Typical Experimental Procedure for the Pd Catalyzed Allyl Ester Removal
(54/57)

Compound 53/56 (3.41 mmol) was dissolved in dry DCM (30 mL) under argon.
Morpholine (3 mL, 34.1 mmol, 10 equiv.) was added followed by Pd(PPh3)4 (0.43 g, 0.341
mmol, 0.1 equiv.). The solution was stirred for 30 minutes and then was washed with 1N
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HCl (2 x 50 mL). A precipitate formed which was kept with the organic layer. The
organic layer is dried over Na2SO4 and evaporated to yield a yellow residue. The residue is
taken up in CHCl3:MeOH (9:1) and purified by flash column chromatography to yield
54/57 , as a yellow oil in 83-87%.
Tert-butyl (2S)-2-N-1-[(5-carboxy)-(4R)-bis(N´, N´-tert-butoxycarbonylamino) pentyl]2-amino-3-methyl-butanoate (54a) 1H NMR (250 MHz, CDCl3) d 0.98 (m, 6H), 1.47 (s,
9H), 1.48 (s, 18H), 1.62 (m, 1H), 2.18 (m, 6H), 2.66 (m, 2H), 3.12 (d, 1H), 4.66 (m, 1H).
13
C NMR (62.5 MHz, CDCl3) d 18.27, 19.56, 26.37, 28.22, 28.34, 28.49, 30.93, 47.74,
50.92, 59.28, 66.96, 82.24, 82.76, 152.76, 172.08, 176.34. FAB-MS 489 (M+H)+.
Tert-butyl (2S)-2-N-1-[(5-carboxy)-(4R)-bis(N´, N´-tert-butoxycarbonylamino) pentyl]2-amino-4-methyl-pentanoate (54b) 1H NMR (250 MHz, CDCl3) d 0.95 (m, 6H), 1.50
(s, 27H), 1.74 (m, 6H), 2.34 (m, 1H), 2.72 (m, 1H), 2.90 (m, 1H), 3.49 (t, 1H), 4.71 (m,
1H), 8.46 (broad, 2H). 13C NMR (62.5 MHz, CDCl3) d 21.94, 23.60, 25.32, 25.46, 28.39,
28.45, 28.73, 40.48, 46.92, 58.83, 60.04, 83.07, 83.50, 152.69, 171.69, 174.62. FAB-MS
503 (M+H)+.
Methyl (2S)-2-N-1-[(5-carboxy)-(4R)-bis(N´, N´-tert-butoxycarbonylamino) pentyl]-2amino-3-phenyl-propanoate (57) 1H NMR (250 MHz, CDCl3) d 1.47 (s, 18H), 1.61(m,
2H), 1.86 (m, 1H), 2.16 (m, 1H), 2.67 (m, 2H), 2.99 (m, 1H), 3.12 (m, 1H) 3.58 (s, 3H),
3.71 (t, 1H), 4.72 (t, 1H), 7.15-7.26 (m, 5H), 8.16 (broad, 2H). 13C NMR (250 MHz,
CDCl3) d 26.03, 27.70, 38.48, 46.93, 51.70, 58.28, 62.16, 82.64, 126.77, 128.36, 129.12,
136.22, 152.29, 173.39, 174.68. FAB-MS 495 (M+H)+.
3. 6

Typical Experimental Procedure for Cyclization (55/58)

Compound 54/57 (3.09 mmol) was dissolved in dry CH3CN (22 mL) and kept
under argon. HATU or PyOAP (3.09 mmol, 1 equiv.) was added, followed by DIEA (1.13
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mL, 6.49 mmol, 2.1 equiv.). The solution was stirred for 2 hours after which the solvent
was removed under reduced pressure. The residue was taken up in hexanes:ethyl acetate
(3:1) and purified by flash column chromatography to give 55/58 as a white solid, 75-77%.
Tert-butyl 3-(R)-N´,N´-[(tert-butoxy)carbonyl]-amino-1-[1-(S)-methylethylethanoate]2-piperidinone (55a) 1H NMR (250 MHz, CDCl3) d 0.98 (m, 6H), 1.44 (s, 9H), 1.49 (s,
18H), 1.69 (m, 1H), 1.84 (m, 2H), 2.15 (m, 2H), 3.28 (m, 1H), 3.56 (m, 1H), 4.78 (m, 1H),
4.92 (d, 1H). 13C NMR (62.5 MHz, CDCl3) d 19.49, 19.96, 22.84, 27.10, 27.94, 28.31,
43.85, 57.06, 61.99, 81.42, 82.71, 152.97, 168.45, 170.73. FAB-MS 472 (M+H)+. anal.
calcd for C24H42N2O7 (%): C 61.24, H 9.00, N, 5.95. found: C 61.03, H 8.65, N 6.02.
Tert-butyl
3-(R)-N´,N´-[(tert-butoxy)carbonyl]-amino-1-[1-(S)-2methylpropylethanoate]-2-piperidinone (55b) 1H NMR (250 MHz, CDCl3) d 0.93 (m,
6H), 1.44 (s, 9H), 1.49 (s, 18H), 1.66 (m, 3H), 1.93 (m, 2H), 2.03-2.30 (m, 2H), 3.24 (m,
2H), 4.78 (m, 1H), 5.33 (m, 1H). 13C NMR (250 MHz, CDCl3) d 22.68, 23.56, 24.74,
25.49, 28.04, 29.21, 29.26, 38.67, 44.94, 55.69, 58.02, 82.34, 83.58, 153.75, 169.18,
172.78. FAB-MS 485 (M+H)+.
Methyl-3-(R)-N´,N´-[(tert-butoxy)carbonyl]-amino-1-[1-(S)-benzylethanoate]-2piperidinone (58) 1H NMR (250 MHz, CDCl3) d 1.49 (s, 18H), 1.50-1.67 (m, 1H), 1.76
(m, 1H), 1.97 (m, 1H), 2.14 (m, 1H), 2.91 (m, 1H), 2.18 (m, 1H), 3.18-3.55 (m, 3H), 3.67
(s, 3H), 4.66-4.79 (m, 2H), 7.19-7.30 (m, 5H). 13C NMR (250 MHz, CDCl3) d 21.79,
26.01, 27.52, 33.88, 47.17, 51.53, 56.12, 60.25, 81.90, 126.04, 127.93, 128.51, 137.18,
151.94, 167.54, 170.52. FAB-MS 477 (M+H)+. anal. calcd for C25H36N2O7 (%): C 63.01,
H 7.61, N 5.88. found: C 63.26; H 7.97, N 5.92.
3. 7

Typical Experimental Procedure for Fmoc Protection (47)

Compound 55 (1.80 mmol) was treated with TFA/DCM (1:1, 3.2 mL) and stirred
for 15 minutes. The solvent was evaporated and the resulting oil was dissolved in dry DCM
(20 mL). DIEA (1.27 mL, 7.2 mmol, 4 equiv.) was added and the solution was stirred for
30 minutes. The solution is cooled to 0 °C, and TMS-Cl (0.45 mL, 3.6 mmol, 2 equiv.)
86

was added slowly, and stirred for 2.5 hours at room temperature. The reaction is then
cooled to 0 °C, and Fmoc-Cl (0.51 g, 1.80 mmol, 1 equiv.) dissolved in the minimum
amount of dry DCM was added.

The reaction mixture is stirred overnight at room

temperature and the DCM is evaporated. The residue was taken up in ether:2.5% Na2CO3
(1:1, 70 mL), the aqueous layer was separated, and washed with ether (2 x 50 mL). The
aqueous layer was treated with 1N HCL until a white precipitate forms, pH 1-2. The
mixture is then extracted with ethyl acetate (3 x 50), dried with Na2SO4, and evaporation of
ethyl acetate yielded the resulting product (47) as a white solid (78-85%).
3-(R)-N´-[(9H-fluoren-9-ylmethoxy)carbonyl]-amino-1-[1-(S)-methylethylethanoic
acid]-2-piperidinone (47a) 1H NMR (250 MHz, CDCl3) d 0.96 (d, 3H), 1.09 (d, 3H), 1.28
(m, 1H), 2.07 (m, 2H), 2.45 (m, 2H), 3.47 (m, 2H), 4.26 (m, 3H), 4.41 (d, 1H), 5.86 (m,
1H), 7.52 (m, 8H). 13C NMR (62.5 MHz, CDCl3) d 19.17, 19.99, 20.49, 26.61, 27.15,
45.08, 47.09, 51.79, 64.78, 67.08, 119.89, 125.16, 127.05, 127.65, 141.26, 143.81, 143.91,
156.34, 171.38, 173.43. FAB-MS 437 (M+H)+.
3-(R)-N´-[(9H-fluoren-9-ylmethoxy)carbonyl]-amino-1-[1-(S)-2-methylpropylethanoic
acid]-2-piperidinone (47b) 1H NMR (250 MHz, CDCl3) d 0.92 (m, 6H), 1.27 (m, 2H),
1.37-1.62 (m, 2H), 1.79 (t, 2H), 2.06 (m, 2H), 2.46 (m, 1H), 3.34 (m, 1H), 4.22 (m, 2H),
4.35 (m, 1H), 4.95 (m, 1H), 6.11 (m, 1H), 7.25-7.65 (m, 8H), 10.57 (broad, 1H). 13C NMR
(62.5 MHz, CDCl3) d 21.13, 21.86, 23.63, 25.40, 27.23, 37.30, 44.90, 47.52, 52.29, 56.65,
67.55, 120.33, 125.59, 127.49, 128.09, 141.69, 144.23, 156.89, 172.18, 175.81. FAB-MS
451 (M+H)+.
3. 8

Typical Experimental Procedure for Removal of Methy Ester (48)
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Compound 58 (1.49 g, 3.25 mmol) is dissolved in a mixture of MeOH (20 mL) and
1N NaOH (4.80 mL) and stirred at room temperature overnight. MeOH is removed in
vacuo and the residue is diluted with water (50 mL). The aqueous solution is extracted
with ethyl acetate (2x25 mL) and acidified with 10% NaHSO4, pH=1-2, and extracted with
ethyl acetate (3x50 mL). The combined organic layers were washed with water, dried over
MgSO4, and removed in vacuo to yield 48, in 95%. 1H NMR (250 MHz, CDCl3) d 1.49 (s,
18H), 1.72 (m, 1H), 2.05 (m, 2H), 2.92 (m, 1H), 3.30 (m, 3H), 4.74 (m, 2H), 7.21-7.29 (m,
5H), 10.69 (broad s, 1H).

13

C NMR (250 MHz, CDCl3) d 21.83, 26.18, 27.85, 34.11,

48.25, 56.29, 62.61, 82.86, 126.58, 128.41, 128.86, 137.13, 152.23, 169.49, 173.70. FABMS 463 (M+H)+.
3. 9

Typical Experimental Procedure for Schiff Base Formation (64)

The HCl salt of the amino acid 63 (25.5 mmol) is dissolved in dry THF (25 mL)
and brought to 0 °C. Then MgSO4 (5.1 g), benzaldehyde (51 mmol, 2 equiv.), TEA (25.5
mmol, 1 equiv.) are added and stirred at RT under argon for 5 hours. The reaction mixture
is filtered and solvent is evaporated under reduced pressure, giving imine 64 as yellow oil,
along with excess benzaldehyde in quantitative yield.
Methyl N-benzylidine-(S)-valinate (64a). 1H NMR (250 MHz, CDCl3) d 0.94 and 0.97
(2d,J = 6.7, 6H), 2.46-2.32 (m, 1H), 3.66 (d, 1H), 3.74 (s, 3H), 7.40-7.43 (m, 3H), 7.777.81 (m, 2H), 8.24 (s. 1H) 13C NMR (250 MHz, CDCl3) d 19.02, 19.88, 32.09, 46.20,
52.33, 80.77, 128.94, 131.45, 136.03, 163.69, 172.84.
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Methyl N-benzylidine-(S)-leucinate (64b). 1H NMR (250 MHz, CDCl3) 0.88 and 0.93
(2d, J = 6.5, 6H), 1.59-1.65 (m, 1H), 1.76-1.94 (m, 2H), 3.69 (s, 3H), 4.0-4.11 (m, 1H),
7.28-7.40 (m, 3H), 7.75-7.78 (m, 2H), 8.27 (s, 1H). 21.89, 23.57, 24.81, 42.49, 52.45,
128.94, 128.98, 131.50, 136.10, 163.52, 173.20. FAB-MS 234 (M+H)+.
Methyl N-benzylidine-(S)-isoleucinate (64c). 1H NMR (250 MHz, CDCl3) d 0.84-0.95
(m, 6H), 1.04-1.25 (m, 1H), 1.45-1.61 (m, 1H), 2.08-2.25 (m, 1H), 3.70 (s, 3H), 3.74 (d,
1H), 7.39-7.39 (m, 3H), 7.75-7.78 (m, 2H), 8.22 (s, 1H). 13C NMR (250 MHz, CDCl3) d
11.46, 16.17, 25.51, 38.44, 52.25, 79.78, 128.97, 131.46, 136.10, 163.66, 172.79. FABMS 234 (M+H)+.
Methyl N-benzylidine-(S)-methioninate (64d). 1H NMR (250 MHz, CDCl3) d 2.02 (s,
3H), 2.30-2.57 (m, 4H), 3.01 (s, 3H), 4.15-4.20 (m, 1H), 7.24-7.73 (m, 5H). FAB-MS 252
(M+H)+.
Methyl N-benzylidine-(S)-phenylalaninate (64e). 1H NMR (250 MHz, CDCl3) d 3.113.44 (m, 2H), 3.75 (s, 3H), 4.18-4.23 (m, 1H), 7.20-7.72 (m, 10H), 7.79 (s, 1H). 13C NMR
(250 MHz, CDCl3) d 40.22, 52.70, 75.46, 127.03, 128.78, 128.93, 128.98, 130.19, 131.55,
135.94, 137.82, 164.33, 172.54. FAB-MS 268 (M+H)+.
3. 10

Typical Experimental Procedure for Reduction (65)

The Schiff base 64 (25.5 mmol)/benzaldehyde mixture from the previous step is
dissolved in dry MeOH (75 mL) and NaBH4 (3.86 g, 102 mmol, 4 equiv.) is slowly added.
The reaction mixture is stirred under argon for 30 minutes, quenched with 1N NaOH (20
mL), and extracted 3 times with ether. Combined ether layers are extracted with saturated
NaCl solution, dried with Na2SO4, and evaporated under reduced pressure. The benzyl
alcohol was removed under high vacuum at RT, giving amine 65 as colorless oil, yield 9095 %.
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Methyl N-benzyl-(S)- valinate (64a). 1H NMR (250 MHz, CDCl3) d 0.96 and 0.99 (2d, J
= 4.45, 6H), 1.85 (broad, 1H), 1.98-2.01 (m, 1H), 3.04 (d, 1H), 3.60 (d, 1H), 3.70 (s, 3H),
3.85 (d, 1H), 7.45 (m, 5H). ). 13C NMR (250 MHz, CDCl3) d 19.04, 19.78, 32.14, 51.67,
52.97, 66.92, 127.38, 128.67, 140.55, 176.07. FAB-MS 222 (M+H)+.
Methyl N-benzyl-(S)- leucinate (64b). 1H NMR (250 MHz, CDCl3) d 0.86 and 0.93 (2d,
J = 6.6, 6H), 1.49 (t, 2H), 1.73-1.89 (m, 2H), 3.32 (t, 1H), 3.63 (d, 1H), 3.70 (s, 3H), 3.87
(d, 1H), 7.20-7.35 (m, 5H). 13C NMR (250 MHz, CDCl3) d 22.56, 23.26, 25.27, 43.26,
51.93, 52.59, 59.59, 127.42, 128.67, 128.72, 140.37, 176.87. FAB-MS 236 (M+H)+.
Methyl N-benzyl-(S)- isoleucinate (64c). 1H NMR (250 MHz, CDCl3) d 0.87-0.93(m,
6H), 1.14-1.36 (m, 1H), 1.51-1.79 (m, 2H), 2.00 (broad, 1H), 3.13 (d, 1H), 3.61 (d, 1H),
3.72 (2, 3H), 3.84 (d, 1H), 7.24-7.35 (m, 5H). 13C NMR (250 MHz, CDCl3) d 11.84,
16.07, 25.96, 38.80, 51.71, 52.97, 65.82, 127.40, 128.70, 128.73, 140.46, 176.11. FABMS 236 (M+H)+.
Methyl N-benzyl-(S)- methioninate (64d). 1H NMR (250 MHz, CDCl3) d 1.73-1.97 (m,
3H), 2.02 (s, 3H), 2.51-2.64 (m, 2H), 3.34-3.41 (m, 1H), 3.60 (d, 1H), 3.67 (s, 3H), 3.80 (d,
1H), 7.18-7.72 (m, 5H). 13C NMR (250 MHz, CDCl3) d 15.74, 30.94, 33.03, 52.18, 52.51,
59.88, 127.47, 128.63, 128.74, 140.26, 175.89. FAB-MS 254 (M+H)+.
Methyl N-benzyl-(S)- phenylalaninate (64e). 1H NMR (250 MHz, CDCl3) d 1.97 (broad,
1H), 3.06 (d, 2H), 3.65 (t, 1H), 3.69 (s, 3H), 3.73 (d, 1H), 3.91 (d, 1H), 7.25-7.36 (m, 10H).
13
C NMR (250 MHz, CDCl3) d 40.27, 52.05, 52.48, 62.55, 127.20, 127.54, 128.65, 128.86,
128.89, 129.78, 137.92, 140.21, 175.45. FAB-MS 270 (M+H)+.
3. 11

Typical Experimental Procedure for Nitrosoamine Formation (66)

The benzyl protected amine 65 (1.14 mmol) is dissolved in DCM (10 mL), brought
to 0 °C, and tert-butylnitrite (1.25 mmol, 1.1 equiv.) in DCM was added from an addition
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funnel. The mixture is brought to RT, refluxed for 3 hours, and stirred overnight. The
solvent is evaporated under reduced pressure, giving nitrosoamine 66 as yellow oil, yield
100%.
Methyl N-benzyl-N-nitroso-(S)-valinate (66a). 1H NMR (250 MHz, CDCl3) d 7.31-7.20
(m, 5H), 5.06 (d, J = 14.6 Hz, 1H), 4.73 (d, J = 10.2 Hz, 1H), 4.47 (d, J = 14.6 Hz, 1H),
3.47 (s, 3H), 2.68-2.48 (m, 1H), 1.00 (d, J = 6.6 Hz, 3H), 0.8 (d, J = 6.6 Hz, 3H); 13C NMR
(250 MHz, CDCl3) d 169.84, 134.61, 128.90, 128.59, 128.04, 71.37, 52.57, 47.05, 29.05,
19.88, 19.57; FAB-MS 251.2 (M+H)+; anal. calcd. for C13H18N2O3 (%): C 62.40, H 7.19, N
11.19; found: C 62.35, H 7.31, N 11.07.
Methyl N-benzyl-N-nitroso-(S)-leucinate (66b). 1H NMR (250 MHz, CDCl3) d 7.327.10 (m, 5H), 5.14 (dd, J = 5.15, 10.4 Hz, 1H), 4.86 (d, J = 14.8 Hz, 1H), 4.64 (d. J = 14.8
Hz, 1H), 3.56 (s, 3H), 1.89-1.75 (m, 1H), 1.49-1.17 (m, 2H), 0.78-0.71 (m, 6H); 13C NMR
(250 MHz, CDCl3) d 171.08, 134.92, 129.20, 128.95, 128.20, 63.28, 52.93, 47.05, 38.72,
24.73, 23.08, 21.38; FAB-MS 265.2 (M+H)+; anal. calcd. for C14H20N2O3 (%): C 63.59, H
7.63, N 10.60; found: C 63.15, H 7.93, N 10.20.
Methyl N-benzyl-N-nitroso-(S)-isoleucinate (66c). 1H NMR (250 MHz, CDCl3) d 7.317.22 (m, 5H), 5.01 (d, J = 14.6 Hz, 1H), 4.84 (d, J = 10.8 Hz, 1H), 4.57 (d, J = 14.6 Hz,
1H), 3.49 (s, 3H), 2.43-2.26 (m, 1H), 1.34-1.19 (m, 1H), 1.10-0.95 (m, 1H), 0.96 (d, J = 6.7
Hz, 3H), 0.72 (t, J = 7.4 Hz, 3H); 13C NMR (250 MHz, CDCl3) d 169.99, 134.72, 128.92,
128.61, 128.03, 70.06, 52.56, 47.02, 34.86, 25.68, 16.01, 10.70; FAB-MS 265.2 (M+H)+;
anal. calcd. for C14H20N2O3 (%): C 63.59, H 7.63, N 10.60; found: C 63.47, H 7.94, N
10.53.
Methyl N-benzyl-N-nitroso-(S)-methioninate (66d). 1H NMR (250 MHz, CDCl3) d
7.36-7.07 (m, 10H), 5.39-5.31 (m, 2H), 5.25-5.20 (m, 1H), 4.89 (d, J = 14.7 Hz, 1H), 4.63
(d, J = 14.7 Hz, 1H), 4.61-4.58 (m, 1H), 3.59 (s, 3H), 3.45 (s, 3H), 2.41-2.26 (m, 8H), 1.90
(s, 3H), 1.84 (s, 3H); 13C NMR (250 MHz, CDCl3) d 170.61, 168.51, 134.52, 134.39,
129.51, 129.27, 129.22, 129.20, 129.08, 129.45, 63.29, 56.92, 56.12, 53.20, 52.71, 47.82,
31.08, 30.63, 29.73, 27.28, 15.52, 15.34 (the peak intensities were the same for both
isomers, so the signals reported are for both isomers); FAB-MS 253.2 (M+H)+; anal. calcd.
for C13H18N2O3S (%): C 55.30, H 6.42, N 9.92, S 11.36; found: C 55.75, H 6.65, N 9.94, S
11.24.
Methyl N-benzyl-N-nitroso-(S)-phenylalaninate (66e). 1H NMR (250 MHz, CDCl3) d
7.33-6.87 (m, 20H), 5.42-5.28 (m, 2H), 5.12 (dd, J = 6.0, 9.8 Hz, 1H), 4.89 (d, J = 14.9 Hz,
1H), 4.5 (d, J = 14.9 Hz, 1H), 4.39-4.33 (m, 1H), 3.63 (s, 3H), 3.51 (s, 3H), 3.38-3.30 (m,
2H), 3.09-2.99 (m, 2H); 13C NMR (250 MHz, CDCl3) d 170.18, 168.05, 137.16, 136.42,
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133.95, 133.86, 129. 55, 129.49, 129.23, 129.18, 129.14, 129.08, 128.83, 128.19, 127.57,
127.48, 65.84, 59.75, 57.33, 53.15, 52.67, 48.00, 36.96, 33.90 (the peak intensities were the
same for both isomers so the signals reported are for both isomers; two aromatic C's did not
appear, we believe due to overlap); FAB-MS 229.17 (M+H)+; anal. calcd. for C17H18N2O3
(%): C 68.44, H 6.08, N 9.30; found: C 68.44, H 6.17, N 9.23.
3. 12

Typical Experimental Procedure for Hydrazine Formation (67)

The nitrosoamine 66 (1.60 mmol) is dissolved in dry MeOH (15 mL) under argon
and charged with conc. HCl (12.8 mmol, 8 equiv.). The reaction mixture is cooled to -78
°C, and activated Zn (12.8 mmol, 8 equiv.) is slowly added to the stirred suspension from a
solid addition funnel, and stirred under argon at -78 °C for 3 hours. The excess Zn is
filtered cold, and the filtrate is treated with cold 6N KOH until strongly basic, pH 12-13,
and extracted with 3 equal portions of cold ether. Ether layers are combined, dried with
Na2SO4, and evaporated under reduced pressure from a RT water bath, yield 88-95%. The
neat oil will oligomerize, so the hydrazines must be characterized quickly or stored at low
temperature as dilute solutions.
Methyl N-Amino-N-Benzyl-(S)-valinate (67a). 1H NMR (250 MHz, CDCl3) d 7.33-7.26
(m, 5H), 3.78 (s, 2H), 3.74 (s, 3H), 3.16 (broad, 2H), 3.03 (d, J = 10.2 Hz, 1H), 2.30-2.15
(m, 1H), 1.09 (d, J = 6.6 Hz, 3H), 0.92 (d, J = 6.7 Hz, 3H); 13C NMR (250 MHz, CDCl3) d
173.66, 138.87, 129.11, 128.83, 127.67, 74.41, 63.16, 51.26, 28.57, 20.16, 20.00; FAB-MS
237.2 (M+H)+.
Methyl N-Amino-N-Benzyl-(S)-leucinate (67b). 1H NMR (250 MHz, CDCl3) d 7.357.28 (m, 5H), 3.97 (d, J = 13.3 Hz, 1H), 3.87 (d, J = 13.3 Hz, 1H), 3.73 (s, 3H), 3.56 (dd, J
= 5.7, 9.1 Hz, 1H), 3.22 (broad, 2H), 1.90-1.83 (m, 2H), 1.62-1.48 (m, 1H), 0.97 (d, J = 6.4
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Hz, 3H), 0.91 (d, J = 6.4 Hz, 3H); 13C NMR (250 MHz, CDCl3) d 174.50, 138.95, 129.21,
128.88, 127.70, 65.68, 62.93, 51.56, 39.39, 25.07, 23.61, 22.01; FAB-MS 251.4 (M+H)+.
Methyl N-Amino-N-Benzyl-(S)-isoleucinate (67c). 1H NMR (250 MHz, CDCl3) d 7.367.26 (m, 5H), 3.77 (s, 2H), 3.76 (s, 3H), 3.16 (d, J = 10.2 Hz, 1H), 3.09 (broad, 2H), 2.161.99 (m, 1H), 1.89-1.73 (m, 1H), 1.46-1.19 (m, 1H), 0.94-0.88 (m, 6H); 13C NMR (250
MHz, CDCl3) d 173.72, 138.82, 129.15, 128.82, 127.67, 72.50, 63.27, 51.24, 34.19, 25.75,
16.08, 10.75; FAB-MS 251.2 (M+H)+.
Methyl N-Amino-N-Benzyl-(S)-methioninate (67d). 1H NMR (250 MHz, CDCl3) d
7.34-7.27 (m, 5H), 3.96 (s, 2H), 3.76 (s, 3H), 3.68 (dd, J = 4.8, 9.9 Hz, 1H), 3.13 (broad,
2H), 2.78-2.60 (m, 2H), 2.32-2.17 (m, 1H), 2.10-1.90 (m, 4H); 13C NMR (250 MHz,
CDCl3) d 173.81, 138.74, 129.23, 128.94, 127.81, 66.04, 63.75, 51.77, 31.44, 29.73, 15.78;
FAB-MS 269.2 (M+H)+.
Methyl N-Amino-N-Benzyl-(S)-phenylalaninate (67e). 1H NMR (250 MHz, CDCl3) d
7.32 (m, 10H); 3.97 (d, J = 13.4 Hz, 1H), 3.89 (d, J = 13.4 Hz, 1H), 3.77-3.66 (m, 1H),
3.73 (s, 3H), 3.22-3.18 (m, 2H); 13C NMR (250 MHz, CDCl3) d 173.35, 139.19, 138.55,
129.71, 129.16, 128.83, 128.62, 127.71, 126.69, 69.38, 63.69, 51.74, 36.35; FAB-MS
285.2 (M+H)+.
3. 13 Benzyl (2R)-4-{2-benzyl-2-[(1S)-1-benzyl-2-methoxy-2-oxoethyl]hydrazino}-2[(tert-butoxycarbonyl)amino]-4-oxobutanoate (69)

Boc-D-Asp-COOBn 68 (1.40 g, 4.35 mmol, 1 equiv.) is dissolved in dry DCM (20
mL) and PyOAP (2.26 g, 4.35 mmol, 1 equiv.) is added followed by TEA (0.667 mL, 4.78
mmol, 1 equiv.). The solution is cooled to 0 °C. Compound 67e in DCM is added
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dropwise from an addition funnel and stirred at 0 °C for 30 min and overnight at room
temperature. The reaction mixture is extracted with cold water, brine and purified by
column chromatography (3:1 hexanes:ethyl acetate). Compound 69 is isolated in 85%
yield as a white semi-solid. 1H NMR (250 MHz, CDCl3) d 1.36, 1.37, and 1.40 (3s, 9H),
2.57 (d, 1H), 2.73-3.17 (m, 2H), 3.56, 3.58, and 3.59 (3s, 3H), 3.63-3.98 (m, 4H), 4.33-4.59
(m, 1H), 5.08-5.11 (m, 2H), 5.51-5.81 (m, 1H), 7.15-7.29 (m, 15H), 6.98 (m, 1H).

13

C

NMR (250 MHz, CDCl3) d 27.99, 33.85-35.78 (m), 49.27-53.25 (m), 61.95, 64.72, 64.93,
66.36, 66.91, 79.22, 127.70-129.505 (m), 135.36-136.18 (m), 155.20, 171.26, 171.31,
172.20. FAB-MS 590 (M+H)+, 490 (M-Boc+H)+. anal. calcd. for C17H18N2O3 (%): C
67.22, H 6.67, N 7.13; found: C 67.01, H 6.17, N 7.06.
3. 14
(2R)-4-{2-[(1S)-1-benzyl-2-methoxy-2-oxoethyl]hydrazino}-2-[(tertbutoxycarbonyl)amino]-4-oxobutanoic acid (71)

Compound 69 (1.83 g, 3.09 mmol) is dissolved in EtOH and 10% Pd/C (0.225 g) is
added and the solution is hydrogenated at 50 psi H2 in a Paar Hydrogenator for 2 hrs. The
reaction mixture is filtered through a celite cake, rinsed with EtOH and evaporation of
EtOH yields 71 in 100%.
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3. 15 Methyl
(2S)-2-({(3R)-3-[(tert-butoxycarbonyl)amino]-2,5-dioxopyrrolidin-1yl}amino)-3-phenylpropanoate (72)

Compound 71 (1.29 g, 3.15 mmol) is dissolved dry acetonitrile (30 mL) and
PyOAP (1.65 g, 3.158 mmol, 1 equiv.) is added followed by DIEA (1.156 mL, 6.63 mmol,
2.1 equiv.). The solution is stirred at room temperature overnight. The solvent is removed
in vacuo, the residue is dissolved in DCM (50 mL) and extracted with 10% NaHSO4 (3x20
mL). The combined organic layers are dried over MgSO4, removed in vacuo and the crude
product is purified by column chromatography (3:1 hexanes:ethyl acetate) which yields 72
in 89% as a white semi-solid. 1H NMR (250 MHz, CDCl3) d 1.40 (s, 9H), 2.56-2.72 (dd,
1H), 2.83-2.99 (dd, 1H), 3.09 (m, 2H), 3.64 (s, 3H), 3.98-4.20 (m, 2H), 5.25 (d, 1H, N-H),
5.52 (d, 1H, N-H), 7.25 (m, 5H).

13

C NMR (250 MHz, CDCl3) d 28.08, 34.22, 37.15,

48.00, 52.28, 61.76, 80.69, 126.88, 128.44, 128.96, 135.98, 155.12, 172.11, 172.48,
173.81. FAB-MS 392 (M+H)+.
3. 16 Methyl (2S)-2-[((3R)-3-{[(4-nitrophenyl)sulfonyl]amino}-2,5-dioxopyrrolidin1-yl)amino]-3-phenylpropanoate (73)
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4M HCl-dioxane (10 mL) is added to compound 72 (0.415 g, 1.06 mmol) and
stirred at 0° C for 2 hrs. The solvent is removed in vacuo followed by high vacuum. The
residue is dissolved in dry DCM and para-nitrobenzylsulfonyl chloride (0.266 g, 1.166
mmol, 1.1 equiv.) is added followed by TEA (0.15 mL, 1.06 mmol, 1 equiv.). The solution
is stirred 48 hrs at room temperature, extracted with 2N HCl, 1N NaHCO3, and brine. The
combined organic layers are dried over MgSO4, removed in vacuo, and purification by
column chromatography yields 73 as a yellow solid in 88%. 1H NMR (250 MHz, CDCl3) d
2.46-2.61 (dd, 1H), 2.76-2.98 (m, 2H), 3.02-3.17 (m, 1H), 3.61 (s, 3H), 4.11 (m, 3H), 5.23
(m, 1H), 6.55 (broad, s, 1H), 7.23 (m, 5H), 8.07 (d, 2H), 8.32 (d, 2H).

13

C NMR (250

MHz, CDCl3) d 34.91, 37.19, 49.65, 52.50, 61.11, 124.35, 127.06, 128.38, 128.60, 135.91,
136.00, 145.72, 150.13, 171.31 171.67, 172.16.
3. 17 Benzyl
(2R)-4-{2-benzyl-2-[(1S)-1-benzyl-2-methoxy-2-oxoethyl]-1-[(tertbutoxycarbonyl)hydrazino]}-2-[bis(tert-butoxycarbonyl)amino]-4-oxobutanoate (74)

Compound 69 (1.045 g, 1.77 mmol) is dissolved in dry acetonitrile and DMAP
(0.086 g, 0.708 mmol, 0.4 equiv.) and t-Boc2O (0.85 g, 3.89 mmol, 2.2 equiv.) are added.
The reaction mixture is stirred at room temperature overnight, acetonitrile is removed in
vacuo and the crude product is purified by column chromatography giving 74 in 88%. 1H
NMR (250 MHz, CDCl3) d 1.46 (s, 27H), 2.58-2.65 (m, 2H), 2.77-3.40 (m, 3H), 3.54 (s,
96

4H), 4.20-4.79 (m, 4H), 7.07-7.48 (m, 15H).

13

C NMR (250 MHz, CDCl3) d 27.58, 32.48,

35.97, 36.22, 51.15, 51.33, 55.04, 67.87, 83.71, 126.12, 127.20, 127.61, 127.88, 128.18,
128.76, 128.95, 135.28, 136.57, 136.62, 151.46, 170.21, 171.79, 172.66, 173.23.
3. 18 (2R)-4-{2-[(1S)-1-benzyl-2-methoxy-2-oxoethyl]hydrazino}-2-[bis(tert-butoxycarbonyl)amino]-4-oxobutanoic acid (75)

Compound 74 (0.702 g, 0.89 mmol) is dissolved in EtOH and 10% Pd/C (0.225 g)
is added and the solution is hydrogenated at 50 psi H2 in a Paar Hydrogenator for 2 hrs.
The reaction mixture is filtered through a celite cake, rinsed with EtOH and evaporation of
EtOH yields 75 in 100%. 1H NMR (250 MHz, CDCl3) d 1.47 (s, 18H), 2.57-2.66 (dd, 1H),
2.86-2.97 (dd, 1H), 3.7 (m, 2H), 3.62 (m, 4H), 4.22 (t, 1H), 5.07 (m, 1H), 5.33 (m, 1H),
7.25 (m, 5H).
3. 19 Methyl (2S)-2-{[(3R)-[bis(tert-butoxycarbonyl)amino]-2,5-dioxopyrrolidin-1yl]amino}-3-phenylpropanoate (77)

Compound 75 (1.119 g, 2.196 mmol) is dissolved dry acetonitrile (30 mL) and
PyOAP (1.14 g, 2.196 mmol, 1 equiv.) is added followed by DIEA (0.804 mL, 4.61 mmol,

97

2.1 equiv.). The solution is stirred at room temperature overnight. The solvent is removed
in vacuo, the residue is dissolved in DCM (50 mL) and extracted with 10% NaHSO4 (3x20
mL). The combined organic layers are dried over MgSO4, removed in vacuo and the crude
product is purified by column chromatography (3:1 hexanes:ethyl acetate) which yields 77
in 78% as a white semi-solid. 1H NMR (250 MHz, CDCl3) d 1.47 (s, 18H), 2.57-2.66 (dd,
1H), 2.84-2.95 (dd, 1H), 3.09 (m, 2H), 3.64 (s, 3H), 4.24 (m, 1H), 5.04 (m, 1H), 5.28 (d,
1H), 7.25 (m, 5H).

13

C NMR (250 MHz, CDCl3) d 27.62, 31.23, 37.11, 51.15, 51.86,

61.44, 84.01, 126.55, 128.13, 128.74, 136.07, 151.09, 171.16, 171.34, 171.60.
3. 20 Tert-butyl
carboxylate (85)

2-benzyl-2-[(1S)-1-benzyl-2-methoxy-2oxoethyl]-hydrazine-

Solid t-Boc2O (0.96 g, 4.32 mmol) is added directly to 67e and stirred together for
30 min at room temperature without any solvent present. After 30 min, a very small
amount of acetonitrile is added and the reaction mixture is stirred overnight. Acetonitrile is
removed in vacuo at cold bath temperatures and the product 85 is isolated by column
chromatography (4:1 hexanes:ethyl acetate) in 86% yield. 1H NMR (250 MHz, CDCl3) d
1.35 (s, 9H), 2.94-3.16 (m, 2H), 3.60 (s, 3H), 3.60-3.75 (m, 1H), 4.04-4.08 (m, 2H), 6.68
(broad, 1H), 7.21 (m, 10H).

13

C NMR (250 MHz, CDCl3) d 27.84, 36.10, 51.11, 61.11,

66.37, 79.37, 126.11, 127.12, 127.79, 127.86, 128.94, 129.03, 136.17, 137.55, 155.02,
172.91.
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3. 21

Tert-butyl 2-[(1S)-1-benzyl-2-methoxy-2oxoethyl]-hydrazinecarboxylate (86)

Compound 75 (0.508 g, 1.32 mmol) is dissolved in MeOH (8 mL) and 10% Pd/C
(0.280 g) is added and the solution is hydrogenated at 45 psi H2 in a Paar Hydrogenator for
3 hrs. The reaction mixture is filtered through a celite cake, rinsed with MeOH and
evaporation of MeOH yields 86 in 100%.

1

H NMR (250 MHz, CDCl3) d 1.40 (s, 9H),

2.96-3.03 (m, 2H), 3.67 (s, 3H), 3.96 (m, 1H), 4.24 (m, 1H), 6.49 (broad, 1H), 7.20-7.25
(m, 5H).

13

C NMR (250 MHz, CDCl3) d 28.00, 36.77, 51.69, 63.90, 80.23, 126.62, 128.29,

129.01, 136.27, 156.02, 172.82.
3. 22

Synthesis of the symmetrical anhydride (96)

Cbz-D-Asp-(COOt-Bu) 87 (0.914 g, 2.82 mmol, 2 equiv.) is dissolved in the
minimum amount of dry DCM and DCC (0.29 g, 1.41 mmol, 1 equiv.) is added and stirred
for 30 min.

The resultant insoluble DCU was removed by filtration, the filtrate is

concentrated in vacuo, giving the desired symmetric anhydride 96 in 98%. 1H NMR (250
MHz, CDCl3) d 1.39 (s, 18H), 2.77-2.83 (m, 4H), 4.61 (m, 2H), 5.09 (s, 4H), 6.06 (d, 2H),
7.27 (m, 10H).

13

C NMR (250 MHz, CDCl3) d 27.50, 36.73, 50.90, 66.80, 81.83, 127.76,

127.82, 128.13, 135.70, 155.48, 165.49, 169.05.
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3. 23 Tert-butyl
(3R)-4-{1-[(1S)-1-benzyl-2-methoxy-2-oxoethyl]-2-tertbutoxycarbonylhydrazino}-3-[(benzyloxycarbonyl)amino]-4-oxobutanoic acid (88)

Compound 86 (0.208 g, 0.706 mmol) is dissolved in the minimum amount of DCM
and added to solid anhydride 96 (0.887 g, 1.41 mmol, 2 equiv.). More DCM is added
dropwise by a syringe until everything goes into solution. The mixture is stirred for 72 hrs.
DCM is removed in vacuo and 88 is isolated by column chromatograph (3:1 hexanes:ethyl
acetate) in 98 %. 1H NMR (250 MHz, CDCl3) d 1.41 (s, 9H), 1.50 (s, 9H), 2.40-2.86 (m,
2H), 2.87-3.28 (m, 2H), 3.56 (s, 3H), 3.74-4.02 (m, 1H), 5.08 (s, 2H), 5.35 (m, 1H), 5.435.77 (m, 1H), 5.82-5.90 (d, 1H), 7.27 (m, 10H).

13

C NMR (250 MHz, CDCl3) d 27.79,

28.00, 37.00, 38.01, 47.67, 51.74, 63.49, 66.56, 80.99, 84.81, 126.54, 126.61, 127.76,
128.18, 128.23, 128.89, 136.15, 136.29, 151.36, 155.38, 169.06, 171.50, 171.68, 172.77.
3. 24 Methyl
(2S)-2-[(5R)-5-{[(benzyloxy)carbonyl]amino}-3,6dioxotetrahydropyridazin-1(2H)-yl]-3-phenylpropanoate (93)
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Compound 88 (0.156 g, 0.261 mmol) was treated with TFA/DCM (1:1, 5 mL) and
stirred for 2 hrs at 0 °C. The solvent was evaporated and the resulting oil was dried under
high vacuum overnight. The residue is dissolved in dry DCM (30 mL) and PyOAP (0.136
g, 0261 mmol, 1 equiv.) is added they are stirred together for 30 min. DIEA (0.095 mL,
0.548 mmol, 2.1 equiv.) is added and the reaction mixture is stirred overnight. DCM is
evaporated and product 93 is isolated by column chromatography (1:1 hexanes:ethyacetate)
in 10 % yield. 1H NMR (250 MHz, CDCl3) d 2.47-2.71 (m, 1H), 2.86-3.18 (m, 3H), 3.67
(s, 3H), 4.04-4.25 (m, 2H), 5.08 (s, 2H), 5.24 (d, 1H), 5.57 (d, 1H).

13

C NMR (250 MHz,

CDCl3) d 34.29, 37.26, 48.29, 52.31, 61.48, 67.44, 126.94, 128.17, 128.37, 128.52, 128.55,
128.95, 136.18, 136.27, 155.71, 171.43, 171.60, 172.76.
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